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ABSTRACT	  	  	  MANUSCRIPT	  1:	   INCIDENCE,	  PREDICTORS	  AND	  IMPACT	  OF	  AMPHOTERICIN	  B	   NEPHROTOXICITY	   ON	   HOSPITAL	   MORTALITY	   USING	   NEWER	   ACUTE	  KIDNEY	   INJURY	   DIAGNOSTIC	   CRITERIA:	   Studies	   on	   amphotericin	   B	   (AmB)	  nephrotoxicity	  use	  diverse	  definitions	  of	  acute	  kidney	  injury	  (AKI).	  Herein,	  we	  used	  the	  new	  KDIGO	  system	  to	  describe	  the	  incidence,	  predictors	  and	  impact	  of	  AmB-­‐induced	  AKI	  on	  hospital	  mortality	   in	  162	  patients	   treated	  with	  AmB	  (120	   deoxycholate	   and	   42	   liposomal).	   KDIGO	   stage	   1	   requires	   an	   absolute	  increase	   ≥0.3	  mg/dl	   or	   ≥1.5x	   over	   baseline	   serum	   creatinine	   (SCr);	   stage	   2	  ≥2x,	   and	   stage	  3	  ≥3x.	  A	  binary	  KDIGO	  definition	   (KDIGObin)	   corresponds	   to	  stage	   ≥	   1.	   For	   comparison,	   we	   included	   two	   definitions	   of	   AKI	   traditionally	  utilized	   in	   nephrotoxicity	   studies:	   ≥0.5	   mg/dl	   (NT0.5)	   and	   ≥2x	   (NT2x)	  increase	   in	   baseline	   SCr.	   The	   overall	   incidence	   of	   AmB-­‐induced	   AKI	   by	  KDIGObin	  was	  58.6%	  (staged	  as:	  1=30.9%;	  2=18.5%	  and,	  3=9.3%).	  Predictors	  of	   AKI	   by	   KDIGObin	   were	   older	   age	   and	   use	   of	   furosemide	   and	   ACE-­‐I.	  Traditional	   criteria	   detected	   lower	   incidences	   of	   AKI:	   45.1%	   (NT0.5)	   and	  27.8%	  (NT2x).	  Predictors	  of	  AKI	  by	  traditional	  criteria	  were	  older	  age	  and	  use	  of	   vancomycin	   (NT0.5)	   and	   use	   of	   vancomycin	   and	   vasopressors	   (NT2x).	  KDIGObin	   detected	   AKI	   2	   days	   earlier	   than	   the	   most	   sensitive	   traditional	  criteria.	   However,	   only	   traditional	   criteria	   were	   associated	   with	   ICU	  admission,	  mechanical	  ventilation	  and	  mortality.	  In	  conclusion,	  the	  increase	  in	  sensitivity	  of	  KDIGObin	   is	   accompanied	  by	  a	   loss	  of	   specificity	  and	  ability	   to	  predict	  outcomes.	  Prospective	  studies	  are	  required	  to	  weigh	  the	  potential	  gain	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from	   early	   AKI	   detection	   against	   the	   potential	   loss	   from	   undue	   changes	   in	  management	  in	  patients	  with	  subtle	  elevations	  in	  SCr.	  	  	  	  MANUSCRIPT	   2:	   ROLE	   OF	   URINE	   NEUTROPHIL	   GELATINASE-­‐ASSOCIATED	  LIPOCALIN	  IN	  THE	  EARLY	  DIAGNOSIS	  OF	  AMPHOTERICIN	  B-­‐INDUCED	  ACUTE	  KIDNEY	   INJURY:	   Neutrophil	   Gelatinase-­‐Associated	   Lipocalin	   (NGAL)	   detects	  acute	   kidney	   injury	   (AKI)	   earlier	   than	   serum	   creatinine	   (SCr)	   in	   cardiac	  surgery,	  contrast	  nephropathy	  and	  intensive	  care	  units.	  We	  hypothesized	  that	  urine	  NGAL	   (UrNGAL)	  would	   be	   an	   early	   biomarker	   of	   drug	   nephrotoxicity.	  We	   studied	   hemodynamically	   stable	   patients	   treated	   with	   Amphotericin	   B	  (AmB).	  We	  measured	  SCr	  and	  UrNGAL	  at	  baseline	  and	  daily	  after	  initiation	  of	  AmB	   up	   to	   day	   14	   or	   development	   of	   AKI	   by	   SCr	   criteria.	   AKI	   was	   defined	  according	   to	   Kidney	   Diseases	   Improving	   Global	   Outcomes	   (KDIGO)	   criteria	  (increase	   in	   SCr	   by	   ≥0.3	   mg/dl	   within	   48	   hours	   or	   ≥1.5x	   baseline	   within	   7	  days).	  We	  studied	  24	  patients	  with	  a	  mean	  age	  of	  48.4±16.4	  years.	  Most	  were	  male	  and	  received	  AmB	  (12	  deoxycholate	  and	  12	  liposomal)	  for	  the	  treatment	  of	   leishmaniasis	  (91.7%).	  Overall,	  17/24	  patients	   fullfilled	  KDIGO	  criteria	   for	  AKI.	   Peak	  UrNGAL	   levels	  were	  higher	   in	  AKI	   than	   in	  No	  AKI	  patients	   and	   in	  recipients	   of	   deoxycholate	   than	   liposomal	  AmB.	  The	  diagnostic	   performance	  of	  UrNGAL	  on	  day	  5	   to	  detect	  AKI	  was	  moderate,	  with	  an	  AUC	  0.68	  (95%	  CI	  0.41-­‐0.95).	  In	  the	  deoxycholate	  subgroup,	  however,	  the	  AUC	  rose	  to	  0.89	  (95%	  CI	  0.67-­‐	  1.00).	   In	  a	  patient-­‐level	  analysis,	  we	   found	  that	  UrNGAL	  was	  able	   to	  detect	  AKI	  3.2	  days	  earlier	  than	  SCr	  (3.7±2.5	  vs.	  6.9±3.3	  days,	  time	  to	  AKI	  by	  UrNGAL	   and	   SCr	   criteria,	   respectively;	   p=0.001).	   Future	   studies	   should	  evaluate	  if	  a	  UrNGAL-­‐oriented	  treatment	  strategy	  will	  improve	  outcomes.	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ABSTRACT	  	  Studies	   on	   amphotericin	   B	   (AmB)	   nephrotoxicity	   use	   diverse	   definitions	   of	  acute	  kidney	  injury	  (AKI).	  Herein,	  we	  used	  the	  new	  KDIGO	  system	  to	  describe	  the	   incidence,	   predictors	   and	   impact	   of	   AmB-­‐induced	   AKI	   on	   hospital	  mortality	   in	   162	   patients	   treated	   with	   AmB	   (120	   deoxycholate	   and	   42	  liposomal).	  KDIGO	  stage	  1	  requires	  an	  absolute	  increase	  ≥	  0.3	  mg/dl	  or	  ≥	  1.5x	  over	  baseline	  serum	  creatinine	  (SCr);	  stage	  2	  ≥	  2x,	  and	  stage	  3	  ≥	  3x.	  A	  binary	  KDIGO	   definition	   (KDIGObin)	   corresponds	   to	   stage	   ≥	   1.	   For	   comparison,	  we	  included	  two	  definitions	  of	  AKI	  traditionally	  utilized	  in	  nephrotoxicity	  studies:	  ≥	   0.5	   mg/dl	   (NT0.5)	   and	   ≥	   2x	   (NT2x)	   increase	   in	   baseline	   SCr.	   The	   overall	  incidence	  of	  AmB-­‐induced	  AKI	  by	  KDIGObin	  was	  58.6%	  (staged	  as:	  1	  =	  30.9%;	  2	  =	  18.5%	  and,	  3	  =	  9.3%).	  Predictors	  of	  AKI	  by	  KDIGObin	  were	  older	  age	  and	  use	  of	  furosemide	  and	  ACE-­‐I.	  Traditional	  criteria	  detected	  lower	  incidences	  of	  AKI:	   45.1%	   (NT0.5)	   and	   27.8%	   (NT2x).	   Predictors	   of	   AKI	   by	   traditional	  criteria	  were	  older	  age	  and	  use	  of	  vancomycin	  (NT0.5)	  and	  use	  of	  vancomycin	  and	  vasopressors	  (NT2x).	  KDIGObin	  detected	  AKI	  2	  days	  earlier	  than	  the	  most	  sensitive	   traditional	   criteria.	   However,	   only	   traditional	   criteria	   were	  associated	   with	   ICU	   admission,	   mechanical	   ventilation	   and	   mortality.	   In	  conclusion,	  the	  increase	  in	  sensitivity	  of	  KDIGObin	  is	  accompanied	  by	  a	  loss	  of	  specificity	  and	  ability	  to	  predict	  outcomes.	  Prospective	  studies	  are	  required	  to	  weigh	   the	   potential	   gain	   from	   early	   AKI	   detection	   against	   the	   potential	   loss	  from	  undue	  changes	  in	  management	  in	  patients	  with	  subtle	  elevations	  in	  SCr.	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INTRODUCTION	  
Amphotericin	  B	  (AmB)	  is	  a	  powerful	  antifungal,	  antiparasitic	  agent	  that	  binds	  to	   the	   ergosterol	   component	   of	   microbial	   membranes,	   creating	   pores	   that	  result	   in	  cation	   leakage	  and	  cell	  death	  (1).	  AmB	   is	   the	  drug	  of	  choice	   for	   the	  treatment	  of	  severe	  forms	  of	  leishmaniasis	  and	  remains	  a	  lifesaving	  option	  for	  certain	   invasive	   fungal	   infections.	  Nevertheless,	   its	  use	   is	   limited	  by	   toxicity,	  including	  acute	  kidney	  injury	  (AKI).	  AmB	   administration	   leads	   to	   direct	   renal	   vasoconstriction	   and	   causes	   a	  profound	   reduction	   in	   renal	   blood	   flow	   (2–4).	   In	   addition,	   AmB	   alters	   renal	  tubular	   cell	   membrane	   permeability	   (5,	   6),	   allowing	   back	   diffusion	   of	  hydrogen	  ion	  and	  thereby	  impairing	  acid	  excretion.	  Recent	  data	  suggests	  that	  sodium	  entry	   through	  membrane	  pores	  activates	  MAP	  kinases	  and	   increases	  intracellular	   calcium	   concentration,	   culminating	   in	   renal	   tubular	   cell	   injury	  (7).	   Therefore,	   AmB-­‐induced	   AKI	   appears	   to	   result	   from	   a	   combination	   of	  ischemic	   and	   toxic	   insults	   (8).	   	   Phenotypically,	   AmB-­‐induced	   AKI	   manifests	  itself	  through	  elevation	  in	  serum	  creatinine	  (SCr)	  that	  may	  be	  accompanied	  by	  a	  renal	  tubular	  acidosis,	  characterized	  by	  hyperchloremic	  metabolic	  acidosis,	  hypokalemia	  and	  hypomagnesemia.	  	  Mistro	  and	  coworkers	  systematically	  reviewed	  the	  literature	  on	  AmB-­‐induced	  AKI	  and	  assessed	  whether	  drug	  delivery	   in	  a	   locally	  prepared	   lipid	  emulsion	  or	   in	   liposomes	  reduced	  nephrotoxicity	  (9).	   In	  their	  metanalysis,	   the	  authors	  summarized	  nine	  clinical	   trials	  comparing	  AmB	  in	  5%	  dextrose	  with	  AmB	  in	  lipid	   emulsion	   and	   found	   an	   overall	   incidence	   of	   nephrotoxicity	   in	   30,6%	  versus	   12,2%,	   respectively.	   They	   also	   summarized	   five	   clinical	   trials	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comparing	   AmB	   in	   5%	   dextrose	   with	   liposomal	   AmB;	   the	   incidences	   of	  nephrotoxicity	  were	  32,5%	  versus	  14,5%,	  respectively.	  Nevertheless,	  a	  closer	  look	  at	   individual	  clinical	   trials	   included	   in	   the	  metanalysis	  uncovers	  several	  issues.	  Most	   studies	  were	   small	   (only	   four	  had	  more	   than	  100	  patients);	   the	  populations	   were	   quite	   different	   and;	   the	   incidences	   of	   AmB-­‐induced	  nephrotoxicity	  varied	  widely,	  ranging	  from	  1.3	  %	  (10)	  to	  100%	  (11)	  for	  AmB	  in	  5%	  dextrose,	  1.2%	  (10)	  to	  33.3%	  (12)	  for	   	  AmB	  in	  lipid	  emulsion	  and	  0%	  (13)	   and	  18.7%	   for	   liposomal	  AmB	   (14).	  Most	   importantly,	   the	   definition	   of	  nephrotoxicity	  across	   trials	  was	   inconsistent.	   Since	   the	   trials	   included	   in	   the	  metanalysis	   by	   Mistro	   et	   al.	   were	   published	   more	   than	   13	   years	   ago	   (all	  between	   1992	   and	   2002),	   none	   of	   them	   used	   currently	   accepted	   consensus	  definitions	   of	   AKI	   (15–17).	   Several	   different	   AKI	   criteria	  were	   used,	   but	   the	  most	  common	  were	  a	  ≥	  0.5	  mg/dl	  increase	  in	  baseline	  serum	  creatinine	  or	  ≥	  50%	   decrease	   in	   estimated	   glomerular	   filtration	   rate	   (GFR)	   (18)	   and	   a	  doubling	  of	  baseline	  SCr	  (13,	  14,	  19,	  20).	  	  The	   first	   consensus	   criteria	   for	  AKI	  was	  published	   in	  2004	  and	  called	  RIFLE	  (Risk,	  Injury,	  Failure,	  End	  stage)	  (15).	  In	  2007,	  the	  RIFLE	  criteria	  was	  modified	  to	   create	   the	   AKIN	   (Acute	   Kidney	   Injury	   Network)	   criteria	   (16).	   Finally,	   in	  2012,	   characteristics	   of	   both	   RIFLE	   and	   AKIN	   were	   merged	   to	   create	   the	  KDIGO	  (Kidney	  Disease	  Improving	  Global	  Outcome)	  criteria	  (17).	  The	  KDIGO	  system	   uses	   changes	   in	   SCr	   or	   urine	   output	   to	   diagnose	   and	   stratify	   AKI	   in	  three	  stages.	  Minimal	  changes	  in	  SCr,	  such	  as	  an	  increase	  ≥	  1.5x	  over	  baseline	  or	  an	  abrupt	  (over	  a	  48-­‐hour)	  increase	  in	  ≥	  0.3	  mg/dl	  would	  qualify	  as	  AKI	  by	  KDIGO	  stage	  1.	  A	  doubling	  of	  baseline	  SCr,	  which,	  as	  mentioned	  above,	   is	  the	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criterion	  most	   commonly	   used	   to	   define	   AmB-­‐induced	   AKI	   in	   older	   studies,	  would	  qualify	  as	  KDIGO	  stage	  2.	  A	  tripling	  of	  baseline	  SCr	  or	  need	  for	  dialysis	  is	  defined	  as	  KDIGO	  stage	  3.	  	  Minejima	  et	  al.	   (21)	  demonstrated	  that	   the	  AKIN	  criteria	   facilitated	  the	  early	  detection	   of	   vancomycin-­‐induced	   nephrotoxicity	   when	   compared	   to	  traditional	   nephrotoxicity	   criteria	   (NT,	   defined	   as	   a	   ≥	   0.5	  mg/dl	   increase	   in	  baseline	  SCr	  or	  a	  ≥	  50%	  decrease	  in	  estimated	  GFR).	  To	  our	  knowledge,	  there	  are	   no	   studies	   comparing	   the	   performance	   of	   newer	   versus	   traditional	  diagnostic	  criteria	  on	  AmB-­‐induced	  AKI.	  The	  main	  objective	  of	  this	  study	  was	  to	  identify	  the	  incidence	  and	  predictors	  of	   AmB-­‐induced	   AKI	   according	   to	   currently	   accepted	   staging	   systems.	   In	  addition,	  we	  aimed	  to	  describe	  the	  dynamics	  of	  AmB-­‐induced	  AKI	  and	  assess	  its	  impact	  on	  hospital	  mortality.	  	  
MATERIALS	  AND	  METHODS	  
Site:	   The	   study	   was	   conducted	   at	   Hospital	   Universitário	   Professor	   Edgard	  Santos,	  a	  tertiary	  care	  facility	  affiliated	  with	  the	  Medical	  School	  of	  the	  Federal	  University	  of	  Bahia,	  located	  in	  Salvador,	  Bahia,	  Brazil.	  	  
Design	  and	  population:	  This	  was	  a	  retrospective	  cohort	  study	  of	  inpatients	  treated	  with	  AmB	  between	  2006	  and	  2012.	  The	  year	  2006	  was	  chosen	  because	  it	  was	  the	  first	  year	  after	  the	  introduction	  of	  electronic	  medical	  records	  (EMRs)	  for	  laboratory	  data	  at	  our	  institution	  (August	  2005);	  the	  year	  2012	  was	  the	  date	  of	  the	  initial	  draft	  of	  this	  project.	  According	  to	  our	  inpatient	  pharmacy,	  there	  were	  734	  treatments	  with	  AmB	  during	  that	  period	  of	  time.	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Exclusion	  criteria	  were	  re-­‐treatments	  (in	  these	  cases,	  only	  data	  from	  the	  first	  treatment	  was	  analyzed);	  use	  of	  less	  than	  three	  doses	  of	  AmB;	  age	  less	  than	  18	  years	  old;	  AKI	  or	  hemodialysis	  at	  the	  time	  of	  AmB	  initiation;	  intermittent	  use	  of	  AmB,	  such	  as	  weekly	  use	  in	  “day	  hospital”	  setting;	  use	  of	  non-­‐intravenous	  forms	  of	  AmB	  and;	  missing	  critical	  data.	  
Variables	   collected:	   We	   reviewed	   paper	   charts	   and	   electronic	   medical	  records	  for	  demographic	  variables,	  patient	  location	  (floor	  versus	  ICU),	  reason	  for	   AmB	   use,	   type	   of	   AmB	   used,	   AmB	   regimen,	   total	   AmB	   dose,	   renal	  protection	   strategy	   used,	   renal	   consultation	   (timing,	   recommendations),	  comorbidities	   (Charlson	   comorbidity	   index),	   concomitant	   nephrotoxic	  medications,	   use	   and	   dose	   of	   vasoactive	   drugs,	   serial	   laboratory	   data	   (BUN,	  SCr,	   potassium,	   magnesium	   and	   bicarbonate),	   days	   on	   the	   ventilator	   (if	  applicable),	  days	  in	  the	  ICU	  (if	  applicable),	  days	  in	  the	  hospital,	  and	  in-­‐hospital	  mortality.	  
Definitions:	  AKI	  was	  defined	  and	  staged	  according	  to	  RIFLE	  (15),	  AKIN	  (16)	  and	   KDIGO	   (17)	   criteria.	   For	   comparison,	   we	   also	   defined	   AKI	   using	   two	  traditional	  nephrotoxicity	  (NT)	  criteria	  (21).	  Since	  we	  did	  not	  have	  access	  to	  urinary	  output	  data,	  AKI	  diagnoses	  were	  based	  solely	  on	  the	  magnitude	  of	  the	  increases	  in	  SCr:	  	  -­‐	   NT0.5:	   absolute	   increase	   in	   SCr	   ≥	   0.5	   mg/dl	   over	   baseline	   (no	   additional	  staging	  system);	  -­‐	  NT2x:	  increase	  in	  SCr	  ≥	  2x	  over	  baseline	  (no	  additional	  staging	  system);	  -­‐	  RIFLE	  R:	   increase	   in	  SCr	  ≥	  1.5x	  over	  baseline;	  RIFLE	  I:	   increase	   in	  SCr	  ≥	  2x	  over	  baseline;	  RIFLE	  F:	  increase	  in	  SCr	  ≥	  3x	  over	  baseline.	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-­‐	  AKIN	  stage	   I:	   absolute	   increase	   in	  SCr	  ≥	  0.3	  mg/dl	  over	  baseline	  within	  48	  hours;	  stage	  II:	  increase	  in	  SCr	  ≥	  2x	  over	  baseline;	  stage	  III:	  increase	  in	  SCr	  to	  ≥	  3x	  over	  baseline	  or	  initiation	  of	  dialysis;	  -­‐	  KDIGO	  stage	  1:	  absolute	  increase	  in	  SCr	  ≥	  0.3	  mg/dl	  over	  baseline	  within	  48	  hours	  or	  increase	  in	  SCr	  ≥	  1.5x	  over	  baseline;	  stage	  2:	  ≥	  increase	  in	  SCr	  2x	  over	  baseline;	  stage	  3:	  increase	  in	  SCr	  ≥	  3x	  over	  baseline	  or	  initiation	  of	  dialysis.	  Due	   to	   the	   48-­‐hour	   requirement,	   which	   practically	   entails	   having	   daily	   SCr	  measurements	   (or	   at	   least	   every	   other	   day),	   the	   AKIN	   criteria	   could	   not	   be	  applied	   to	   some	   patients.	   Since	   the	   newest	   KDIGO	   system	   combines	  characteristics	  of	  RIFLE	  and	  AKIN	  criteria,	  we	  chose	  this	  system	  to	  stratify	  AKI	  in	  ordinal	  stages.	  In	  addition,	  we	  used	  binary	  definitions	  for	  RIFLE,	  AKIN	  and	  KDIGO	   (RIFLEbin,	   AKINbin	   and	   KDIGObin).	   In	   these	   binary	   definitions,	   any	  patient	   that	   fulfilled	   criteria	   for	   the	   initial	   stage	   (which	   in	   practice	  means	   a	  stage	  R	  or	  greater	  for	  RIFLE,	  stage	  I	  or	  grater	  for	  AKIN	  or	  stage	  1	  or	  greater	  for	  KDIGO)	  was	  classified	  as	  having	  AKI.	  	  The	   baseline	   SCr	   was	   defined	   as	   the	   value	   obtained	   on	   the	  morning	   of	   day	  zero,	  which	  was	  the	  day	  of	  the	  first	  AmB	  dose.	  If	  a	  SCr	  value	  was	  not	  available	  for	  that	  day,	  we	  used	  the	  value	  nearest	  to	  day	  zero	  or	  the	  admission	  SCr.	  Hypocalemia	  and	  hypomagnesemia	  were	  diagnosed	  when	  at	  least	  one	  of	  three	  conditions	  was	   satisfied:	   1)	   the	   presence	   of	   documented	   K+	   or	  Mg++	   levels	  below	  the	  laboratory’s	  limit	  of	  normal	  during	  AmB	  treatment;	  2)	  a	  history	  of	  replacement	   of	   these	   cations;	   or,	   3)	   when	   these	   electrolyte	   disorders	   were	  listed	  as	  problems	  in	  the	  patient’s	  chart.	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Ethical	  approval:	  The	  study	  was	  approved	  by	  the	  institutional	  review	  board	  of	   Hospital	   Universitário	   Professor	   Edgard	   Santos	   on	   03/11/13	   (protocol	  number	  11123413.1.0000.0049).	  Given	  the	  retrospective	  nature	  of	  the	  study,	  we	  were	  granted	  a	  waiver	  of	  informed	  consent.	  	  
Statistical	   analyses:	   The	   shape	   of	   the	   distribution	   of	   continuous	   data	   was	  analyzed	  using	  histograms	  and	  normality	  tests	  (Shapiro	  Wilk).	  Normal-­‐shaped	  data	  were	  summarized	  using	  mean	  and	  standard	  deviation	  and	  comparisons	  among	   groups	   made	   with	   the	   Student’s	   t	   test;	   non-­‐Gaussian	   data	   were	  summarized	   using	   median	   and	   interquartile	   range	   and	   comparisons	   among	  groups	   made	   with	   the	   Mann	   Whitney	   U	   test.	   Categorical	   data	   were	  summarized	  using	  absolute	  and	  relative	  frequencies	  and	  comparisons	  among	  groups	  made	   with	   the	   chi	   square	   or	   Fisher’s	   exact	   test,	   where	   appropriate.	  Time	  to	  AKI	  was	  analyzed	  in	  two	  different	  ways:	  1)	  by	  summarizing	  the	  mean	  and	  median	   time	   to	  AKI	  only	   in	   those	  who	  developed	  AKI;	  2)	  by	   the	  Kaplan	  Meier	  method.	   For	   those	   patients	  whose	   lengths	   of	   follow	   up	   exceeded	   one	  month,	  the	  survival	  time	  was	  censored	  at	  thirty	  days.	  The	  Kaplan	  Meier	  data	  was	  summarized	  in	  one	  minus	  cumulative	  survival	  graphs	  and	  survival	  curves	  compared	   using	   the	   log-­‐rank	   test.	   Univariate	   logistic	   and	   Cox	   regression	  analyses	  were	  conducted	  to	  identify	  potential	  predictors	  of	  AKI.	  Variables	  with	  a	   p	   value	   <	   0.20	   on	   univariate	   analyses	   were	   included	   in	   multivariate,	  backward,	   logistic	   and	   Cox	   regression	   models	   to	   identify	   independent	  predictors	   of	   AKI.	   A	   similar	   strategy	   was	   utilized	   to	   identify	   independent	  predictors	  of	  death.	  However,	  since	  AKI	  was	  our	  main	  independent	  variable	  in	  time	   to	   mortality	   analyses,	   it	   was	   allocated	   to	   the	   second	   block	   of	   the	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regression	  and	  forced	  into	  the	  final	  model.	  A	  p	  value	  <	  0.05	  on	  final	  analyses	  was	   considered	   statistically	   significant.	   Statistical	   analyses	   were	   conducted	  using	   the	   software	   packages	   STATA	   version	   12.1	   and	   IBM	   SPSS	   Statistics	  version	  20.0.	  
Sample	  size:	  A	  priori	  sample	  size	  calculation	  was	  conducted	  using	  Open	  EPi,	  available	   at	   http://openepi.com/OE2.3/Menu/OpenEpiMenu.htm.	   Assuming	  an	  overall	  nephrotoxicity	  rate	  of	  30%	  and	  a	  precision	  of	  5%,	  a	  sample	  size	  of	  122	  would	  provide	  a	  confidence	  level	  of	  approximately	  80%;	  a	  sample	  size	  of	  186	   patients,	   90%;	   and	   a	   sample	   size	   of	   245	   patients	   would	   provide	   a	  confidence	  level	  of	  95%.	  	  	  
RESULTS	  
Study	  population	  Out	   of	   734	   treatments	   with	   AmB	   that	   occurred	   at	   our	   institution	   between	  2006	  and	  2012,	  72	  consisted	  of	  re-­‐treatments	  and	  were	  excluded.	  Out	  of	   the	  662	   patients	   that	   used	   AmB,	   500	   were	   excluded.	   Our	   final	   sample	   was	  comprised	   of	   a	   cohort	   of	   162	   patients	   treated	   with	   AmB,	   120	   with	   the	  deoxycholate	   42	   with	   the	   liposomal	   preparation	   (Figure	   1.1).	   The	   median	  length	  of	  stay	  in	  the	  hospital	  for	  the	  cohort	  was	  32	  days	  (interquartile	  range,	  IQR	  23	  to	  51	  days).	  Table	  1.1	  shows	  the	  demographic,	  clinical	  and	  laboratory	  characteristics	  of	  the	  final	  sample.	  Patients	  were	  young,	  with	  a	  median	  age	  of	  36,	  and	  there	  was	  a	  slight	  preponderance	  of	  males.	  The	  main	  indications	  for	  AmB	  were	  suspected	  or	   confirmed	   fungal	   infection	   (40.8%),	   leishmaniasis	   (27.8%)	   and	   fever	   of	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unknown	  origin	  (22.2%).	  Only	  23.5%	  had	  a	  Charlson	  comorbidity	   index	  ≥	  4;	  approximately	   1/3	   needed	   to	   be	   treated	   at	   the	   intensive	   care	   unit	   at	   some	  point	   during	   the	   admission.	   Median	   baseline	   laboratory	   values	   were	   within	  normal	  limits.	  	  	  
	  
Figure	   1.1.	   Flow	   chart	   demonstrating	   the	   process	   of	   selection	   of	   the	  
sample	   of	   162	   patients	   treated	   with	   amphotericin	   B	   at	   our	   institution	  
between	   2006	   and	   2012.	   Legend:	   AKI	   =	   acute	   kidney	   injury;	   HD	   =	  hemodialysis	  	  
N	  =	  734	  treatments	  	  	  2006	  -­‐	  2012	  
N	  =	  662	  patients	  	  
n	  =	  162	  patients	  included	  in	  zinal	  analyses	  
Liposomal	  	  n	  =	  42	  Deoxycholate	  	  n	  =	  120	  
Excluded	  n	  =	  500	  patients	  <	  3	  doses	  n	  =	  374	  	  <	  18	  y/o	  n	  =	  30	  	  AKI	  or	  HD	  at	  initiation	  n	  =	  30	  	  Missing	  critical	  data	  n	  =	  34	  	  Day	  hospital	  n	  =	  20	  	  Eye	  drop	  n	  =	  12	  	  
Excluded	  n	  =	  72	  re-­‐treatments	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Table	   1.1.	   Demographic,	   clinical	   and	   laboratory	   characteristics	   of	   162	  
hospitalized	   adults	   treated	   with	   intravenous	   AmB	   at	   a	   university	  
hospital.	  
	   N	  =	  162	  
Age,	  years	  (median,	  IQR),	  n	  =	  152	   36	  [26	  to	  51]	  
Gender	  Male	  Female	   	  92/162	  (56.8%)	  70/162	  (43.2%)	  
Place	  of	  residence	  Rural	  areas	  of	  the	  state	  Capital	  	   	  95/160	  (59.4%)	  65/160	  (40.6%)	  
Indication	  for	  AmB	  	  Tegumentary	  leishmaniasis	  Visceral	  leishmaniasis	  Suspected	  invasive	  fungal	  infection	  Confirmed	  invasive	  fungal	  infection	  Fever	  of	  unknown	  origin	  
Other	  
	  33/162	  (20.4%)	  12/162	  (7.4%)	  26/162	  (16.0%)	  40/162	  (24.8%)	  36/162	  (22.2%)	  
15/162 (9.3%)	  
Charlson	  comorbidity	  index	  0-­‐1	  2-­‐3	  4	  or	  greater	  
	  65/162	  (40.1%)	  59/162	  (36.4%)	  38/162	  (23.5%)	  
Other	  variables	  related	  to	  disease	  severity	  Intensive	  care	  at	  some	  point	  Vasopressor	  drugs	  at	  some	  point	  Mechanical	  ventilation	  
	  53/162	  (32.7%)	  35/162	  (21.6%)	  42/162	  (26.1%)	  
Baseline	  laboratory	  values	  (serum)	  Creatinine,	  mg/dl	  (n	  =	  162)	  BUN,	  mg/dl	  (n	  =	  103)	  Potassium,	  meq/l	  (n	  =	  98)	  Magnesium,	  mg/dl	  (n	  =	  73)	  Bicarbonate,	  meq/l	  (n	  =	  28)	  Lactate,	  mmol/l	  (n	  =	  23)	  
	  0.8	  [0.7	  to	  1.1]	  12.2	  [7.9	  to	  18.2]	  4.0	  [3.6	  to	  4.4]	  1.8	  [1.6	  to	  2.0]	  21.6	  [16.7	  to	  26.3]	  1.6	  [1.2	  to	  2.0]	  Legend:	  AmB	  =	  amphotericin	  B;	  BUN	  =	  blood	  urea	  nitrogen.	  Continuous	  data	  are	  presented	  as	  median	  [25th	  percentile	  to	  75th	  percentile].	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Treatment	  details	  The	  majority	  (83.3%)	  of	  patients	  initiated	  AmB	  at	  the	  ward.	  The	  deoxycholate	  preparation	  was	  used	  by	  74.1%	  of	  patients;	  the	  median	  initial	  and	  total	  doses	  were	  50	  mg	  and	  445	  mg,	  respectively.	  The	  liposomal	  preparation	  was	  used	  by	  25.9%	  of	  patients;	   the	  median	   initial	  and	  total	  doses	  were	  150	  mg	  and	  1400	  mg,	  respectively.	  Median	  duration	  of	  AmB	  treatment	  was	  10	  days.	  The	  median	  dose	   of	   normal	   saline	   used	   at	   the	   beginning	   of	   AmB	   treatment	   was	   1500	  cc/day.	  The	  nephrotoxic	  drug	   that	  was	  most	  commonly	  used	   in	  combination	  with	  AmB	  was	  vancomycin	  (40.1%	  of	  cases).	  	  	  
Incidence	  of	  AmB-­‐induced	  AKI	  The	  overall	   incidence	  of	  AmB-­‐induced	  AKI	  by	   traditional	   criteria	  was	  27.8%	  (45/162)	   for	   NT2x	   and	   45.1%	   (73/162)	   for	   NT0.5	   (Table	   1.2).	   The	   RIFLE	  criteria	   diagnosed	   10	   additional	   cases	   of	   AKI,	   for	   an	   incidence	   of	   51.2%	  (83/162).	  The	  KDIGO	  criteria	  was	  the	  most	  sensitive,	  detecting	  22	  cases	  that	  were	  missed	  by	  the	  NT0.5	  criteria,	  for	  an	  AKI	  incidence	  of	  58.6%	  (95/162).	  	  	  The	  AKIN	  criteria	  could	  not	  be	  applied	  in	  25	  cases	  due	  to	  the	  absence	  of	  SCr	  values	  at	  critical	  time	  points,	  which	  hampered	  our	  ability	  to	  comply	  with	  the	  48-­‐hour	   requirement.	   Since	   the	   KDIGO	   criteria	   combines	   characteristics	   of	  RIFLE	  and	  AKIN,	  this	  system	  was	  chosen	  to	  stratify	  AKI	  in	  stages.	  Most	  cases	  of	  AKI	  were	  mild,	   classified	   as	   stage	   1	   or	   2.	   The	   incidence	   of	   severe,	  KDIGO	  stage	  3-­‐AKI	  was	  less	  than	  10%	  overall	  and	  less	  than	  5%	  in	  patients	  using	  the	  liposomal	  preparation.	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Table	   1.2.	   Influence	   of	   the	   diagnostic	   criteria	   on	   the	   incidence	   of	   AKI	  
during	   intravenous	   AmB	   use	   in	   162	   hospitalized	   adults	   treated	   at	   a	  




(n	  =	  162)	  
Type	  of	  AmB	  
p	  Deoxycholate	  
(n	  =	  120)	   Liposomal	  (n	  =	  42)	  
Binary	  NT2x	  NT0.5	  RIFLEbin	  AKINbin*	  KDIGObin	  
	  45/162	  (27.8%)	  73/162	  (45.1%)	  83/162	  (51.2%)	  72/137	  (52.6%)	  95/162	  (58.6%)	  
	  38/120	  (31.7%)	  59/120	  (49.2%)	  65/120	  (54.2%)	  55/102	  (53.9%)	  72/120	  (60.0%)	  
	  7/42	  (16.7%)	  14/42	  (33.3%)	  18/42	  (42.9%)	  17/35	  (48.6%)	  23/42	  (54.8%)	  
	  0.062	  0.076	  0.207	  0.584	  0.553	  
KDIGO	  
stages#	  Stage	  1	  Stage	  2	  Stage	  3	  
	  	  50/162	  (30.9%)	  30/162	  (18.5%)	  15/162	  (9.3%)	  
	  	  34/120	  (28.3%)	  25/120	  (20.8%)	  13/120	  (10.8%)	  
	  	  16/42	  (38.1%)	  5/42	  (11.9%)	  2/42	  (4.8%)	  







Regarding	  the	  time	  to	  diagnosis	  of	  AKI,	  the	  traditional	  NT0.5	  criteria	  detected	  AmB-­‐induced	  AKI	  at	  a	  median	  of	  6.0	  days	  [IQR	  4.0	  to	  9.0]	  whereas	  the	  newer	  KDIGO	  criteria	  detected	  it	  two	  days	  earlier,	  at	  a	  median	  of	  4.0	  days	  [IQR	  2.0	  to	  7.8]	  (Table	  1.3).	  	  
Table	   1.3.	   Influence	   of	   the	   diagnostic	   criteria	   on	   the	   time	   in	   days	   to	  
diagnosis	  of	  AKI	  during	  intravenous	  AmB	  use	  in	  162	  hospitalized	  adults	  
treated	  at	  a	  university	  hospital,	  stratified	  by	  type	  of	  AmB	  preparation.	  
AKI	  Criteria	  
All	  
(n	  =	  162)	  
Type	  of	  AmB	  
Deoxycholate	  
(n	  =	  120)	   Liposomal	  (n	  =	  42)	  
NT0.5	  (n	  =	  73)	   6.0	  [4.0	  to	  9.0]	   5.0	  [4.0	  to	  9.0]	   7.0	  [4.0	  to	  12.5]	  
NT2x	  (n=45)	   5.0	  [3.0	  to	  8.0]	   5.0	  [3.0	  to	  980]	   6.0	  [4.0	  to	  8.0]	  
KDIGO	  Stage	  1	  (n	  =	  76)	  Stage	  2	  (n	  =	  40)	  Stage	  3	  (n	  =	  15)	  
	  4.0	  [2.0	  to	  7.8]	  5.5	  [3.3	  to	  8.0]	  7.0	  [4.0	  to	  13.0]	  
	  4.0	  [2.5	  to	  7.5]	  5.5	  [3.0	  to	  8.3]	  7.0	  [3.5	  to	  13.0]	  




Figure	  1.2.	  Time	  to	  AKI	  stratified	  by	  AmB	  preparation	  according	  to	  NT0.5	  
and	  KDIGObin	  criteria.	  Legend:	  NT0.5	  =	  traditional	  nephrotoxicity	  criteria	  of	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an	   absolute	   serum	   creatinine	   increase	   ≥	   0.5	   mg/dl	   over	   baseline;	   NT2x	   =	  traditional	   nephrotoxicity	   criteria	   of	   a	   serum	   creatinine	   increase	   ≥	   2x	   over	  baseline.	   	  KDIGO	  =	  Kidney	  Diseases	  Improving	  Global	  Outcomes;	  a	  KDIGObin	  indicates	   an	   absolute	   serum	   creatinine	   increase	   ≥	   0.3	  mg/dl	   or	   ≥	   1.5x	   over	  baseline.	  Solid	  line:	  deoxycholate;	  Dashed	  line:	  liposomal.	  	  (|	  and	  +)	  marks	  on	  the	  survival	   curves	   represent	  censored	  cases.	  Comparison	  among	  one	  minus	  cumulative	  survival	  curves	  for	  the	  two	  AmB	  preparations	  was	  0.069	  using	  the	  NT0.5	  criteria,	  0.081	  using	  NT2x	  (not	  shown)	  and	  0.553	  using	  the	  KDIGObin	  criteria	  (log-­‐rank	  test).	  	  	  
Clinical	  characteristics	  of	  AmB-­‐induced	  AKI	  	  Figure	  1.3	  shows	  mean	  serum	  creatinine	  values	  during	  AmB	  therapy,	  stratified	  by	  the	  presence	  of	  AKI	  by	  KDIGObin.	  In	  the	  AKI	  group,	  mean	  serum	  creatinine	  started	  to	  rise	  at	  day	  two	  and	  peaked	  at	  day	  8.	  Peak	  serum	  creatinine	   in	   the	  AKI	  group	  was	   (mean	  ± SD)	  1.66	  ± 0.67	  mg/dl	  versus	  1.04	  ± 0.38	  mg/dl	   in	  the	  no	  AKI	  group	  (p	  =	  <0.001).	   	  Peak	  serum	  creatinine	  was	  also	  numerically	  higher	  among	  AKI	  patients	  using	  deoxycholate	  versus	   liposomal	  preparation	  (1.69	   ±  0.71	  mg/dl	   versus	   1.58	   ± 0.53	  mg/dl),	   but	   the	   difference	  was	   not	  statistically	  significant	  (p	  =	  0.488).	  
Electrolyte	  imbalances	  	  Regarding	   electrolyte	   imbalances	   during	   AmB	   treatment,	   121/162	   (74.7%)	  fulfilled	   our	   criteria	   for	   hypokalemia	   and	   107/162	   (66.0%)	   required	  potassium	   replacement.	  Both	  hypokalemia	   (80.0%	  versus	  59.5%,	  p	  =	  0.015)	  and	   potassium	   replacement	   (71.7%	   versus	   50.0%,	   p	   =	   0.018)	   were	  significantly	   more	   common	   in	   patients	   using	   the	   deoxycholate	   versus	   the	  liposomal	  preparation.	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Figure	  1.3.	  Serum	  creatinines	  over	  time	  during	  AmB	  use,	  stratified	  by	  the	  
occurrence	   of	   AKI	   according	   to	   the	   KDIGO	   criteria.	   Legend:	   the	   circles	  represent	   the	   AKI	   group	   and	   squares	   represent	   those	   without	   AKI	   by	   the	  KDIGO	   (Kidney	   Diseases	   Improving	   Global	   Outcomes)	   criteria.	   A	   KDIGObin	  indicates	   an	   absolute	   serum	   creatinine	   increase	   ≥	   0.3	  mg/dl	   or	   ≥	   1.5x	   over	  baseline.	  	  Hypomagnesemia	   was	   detected	   in	   101/162	   (62.3%)	   and	   magnesium	  replacement	   was	   required	   by	   89/162	   (54.9%)	   of	   patients.	   Similarly,	  hypomagnesemia	   (68.3%	   versus	   45.2%,	   p	   =	   0.10)	   and	   magnesium	  replacement	  (60.8%	  versus	  38.1%,	  p	  =	  0.012)	  were	  more	  common	  in	  patients	  receiving	  deoxycholate	  versus	  liposomal	  AmB.	  There	  was	  no	  association,	  however,	  between	  these	  electrolyte	  imbalances	  and	  AKI,	  regardless	  of	  the	  AKI	  criteria.	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AKI	  management	  and	  Nephrology	  consult	  	  A	   change	   in	   management	   in	   response	   to	   AKI	   was	   documented	   in	   59/95	  (62.1%)	  patients	  classified	  by	  KDIGObin.	  Changes	  in	  management	  were	  more	  frequent	  in	  stage	  3	  (73%)	  than	  in	  stages	  2	  (66.7%)	  or	  stage	  1	  (56%)	  AKI.	  The	  most	  common	  changes	  were	  to	  discontinue	  AmB	  (n=32);	  increase	  the	  amount	  of	   intravenous	   fluids	   (n=19);	   decrease	   AmB	   dose	   (n=17);	   switch	   from	  deoxycholate	  to	   liposomal	  (n=8);	  switch	  the	  AmB	  regimen	  (e.g.	   from	  daily	  to	  every	  other	  day,	  n	  =	  6),	  and;	  discontinue	  concomitant	  nephrotoxins	  (n=3).	  	  A	  Nephrology	  consult	  was	  performed	  in	  26.3%	  (25/95)	  of	  patients	  with	  and	  in	  6%	   (4/67)	   of	   patients	   without	   AKI	   by	   KDIGObin.	   There	   was	   a	   significant	  association	   between	   nephrology	   consult	   and	   KDIGO	   stage,	   with	   higher	  frequency	  of	  consultation	  occurring	  at	  higher	  stages	  (9.6%	  at	  stage	  1,	  25%	  at	  stage	  2	  and	  86.7%	  at	  stage	  3,	  p	  =	  <0.001).	  The	  median	  time	  from	  initiation	  of	  AmB	   treatment	   to	   nephrology	   consult	   was	   5	   days	   (IQR	   1.0	   to	   8.5).	   Median	  serum	  creatinine	  at	  consultation	  was	  1.4	  mg/dl	  (IQR	  1.2	  to	  2.3).	  Eleven	  patients	  (6.8%)	  required	  dialysis	  at	  a	  median	  of	  9.0	   [IQR	  5.0	   to	  15.0]	  days	  after	  initiation	  of	  AmB.	  Median	  time	  on	  dialysis	  was	  3.0	  days	  [IQR	  0.0	  to	  8.0	  days].	  	  	  
Predictors	  of	  AmB-­‐induced	  AKI	  	  We	  then	  attempted	  to	  identify	  predictors	  of	  AKI.	  For	  these	  analyses,	  we	  used	  both	   logistic	   regression	   (treating	  AKI	   as	   the	  binary	  dependent	   variable)	   and	  Cox	   proportional	   hazards	   (using	   time	   to	   AKI	   as	   the	   dependent	   variable)	  analyses.	   In	   addition,	   we	   conducted	   these	   analyzes	   using	   KDIGObin	   and	  traditional	   NT0.5	   and	   NT2x	   criteria.	   The	   following	   predictor	   variables	  were	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analyzed:	   age	   (continuous),	   type	   of	   AmB	   (deoxycholate	   versus	   liposomal),	  place	   of	   AmB	   initiation	   (ICU	   versus	   ward),	   diagnosis	   (leismaniasis	   versus	  other),	   Charlson	   score	   (≥	   4	   versus	   1	   thru	   3)	   and	   use	   of	   furosemide,	   ACE-­‐I,	  polimixin	  B,	  vancomycin	  and	  vasopressors	  (all	  yes	  versus	  no).	  	  Independent	   predictors	   of	   AKI	   in	   multivariate	   logistic	   regression	   models	  varied	   according	   to	   the	   criteria	   used	   to	   define	   AKI.	   When	   the	   KDIGObin	  criteria	  was	  used,	  age	  and	  use	  of	  furosemide	  were	  marginally	  significant.	  Age	  and	   use	   of	   vancomycin	   were	   predictors	   of	   AKI	   by	   NT0.5	   whereas	   use	   of	  vancomycin	   and	   vasopressors	   predicted	   AKI	   by	   NT2x	   (Table	   1.4).	   Cox	  proportional	  hazards	  models	  yielded	  similar	  findings	  (Table	  1.	  5).	  	  









Table	   1.4.	   Univariate	   and	   multivariate	   logistic	   regression	   analyses	   to	  
identify	  independent	  predictors	  of	  AKI	  by	  KDIGObin,	  NT0.5	  and	  NT2x.	  
	  
AKI	  criteria	  Predictors	   Univariate	   p	   Multivariate	   p	  OR	  (95%	  CI)	   OR	  (95%	  CI)	  
KDIGObin	   	   	   	   	  Age	  (years)	   1.02	  (1.00	  -­‐	  1.04)	   0.066	   1.02	  (1.00	  -­‐	  1.04)	   0.096	  Deoxycholate	  	   1.24	  (0.61	  -­‐	  2.52)	   0.553	   	   	  ICU	  initiation	   1.24	  (0.53	  -­‐	  2.91)	   0.618	   	   	  Leishmaniasis	  	   1.40	  (0.69	  -­‐	  2.85)	   0.353	   	   	  Charlson	  ≥	  4	   1.28	  (0.61	  -­‐	  2.71)	   0.519	   	   	  Furosemide	   2.26	  (1.01	  -­‐	  5.07)	   0.047	   2.30	  (0.98	  -­‐	  5.39)	   0.056	  ACE-­‐I	   2.29	  (0.91	  -­‐	  5.77)	   0.080	   	   	  Polimixin	  B	   0.59	  (0.22	  -­‐	  1.63)	   0.309	   	   	  Vancomycin	   1.22	  (0.64	  -­‐	  2.32)	   0.540	   	   	  Vasopressors	   1.07	  (0.50	  -­‐	  2.30)	   0.854	   	   	  
NT0.5	   	   	   	   	  Age	  (years)	   1.02	  (1.00	  -­‐	  1.04)	   0.064	   1.02	  (1.00	  -­‐	  1.04)	   0.038	  Deoxycholate	  	   1.93	  (0.93	  -­‐	  4.03)	   0.078	   	   	  ICU	  initiation	   1.99	  (0.86	  -­‐	  4.61)	   0.108	   	   	  Leishmaniasis	  	   0.85	  (0.43	  -­‐	  1.71)	   0.653	   	   	  Charlson	  ≥	  4	   1.13	  (0.55	  -­‐	  2.34)	   0.744	   	   	  Furosemide	   2.13	  (1.01	  -­‐	  4.49)	   0.048	   	   	  ACE-­‐I	   1.66	  (0.72	  -­‐	  3.81)	   0.233	   	   	  Polimixin	  B	   0.84	  (0.30	  -­‐	  2.32)	   0.734	   	   	  Vancomycin	   2.01	  (1.06	  -­‐	  3.81)	   0.032	   2.24	  (1.16	  -­‐	  4.32)	   0.016	  Vasopressors	   1.61	  (0.76	  -­‐	  3.41)	   0.218	   	   	  
NT2x	   	   	   	   	  Age	  (years)	   1.00	  (0.98	  -­‐	  1.02)	   0.965	   	   	  Deoxycholate	  	   2.32	  (0.94	  -­‐	  5.69)	   0.067	   	   	  ICU	  initiation	   2.47	  (1.05	  -­‐	  5.81)	   0.038	   	   	  Leishmaniasis	  	   0.47	  (0.20	  -­‐	  1.10)	   0.082	   	   	  Charlson	  ≥	  4	   1.27	  (0.58	  -­‐	  2.81)	   0.550	   	   	  Furosemide	   1.85	  (0.85	  -­‐	  4.02)	   0.080	   	   	  ACE-­‐I	   1.68	  (0.70	  -­‐	  4.02)	   0.243	   	   	  Polimixin	  B	   1.09	  (0.36	  -­‐	  3.30)	   0.874	   	   	  Vancomycin	   2.74	  (1.35	  -­‐	  5.54)	   0.005	   2.27	  (1.09	  -­‐	  4.72)	   0.028	  Vasopressors	   3.34	  (1.52	  -­‐	  7.32)	   0.003	   2.73	  (1.21	  -­‐	  6.16)	   0.015	  Legend:	   Age	   was	   evaluated	   as	   a	   continuous	   variable;	   all	   other	   independent	  variables	   are	   categorical.	   Variables	   with	   p	   <0.20	   in	   univariate	   analyses	   (in	  bold)	   were	   included	   in	   a	   multivariate,	   backward,	   logistic	   regression	   model.	  Only	  the	  variables	  remaining	  at	  the	  final	  model	  are	  shown.	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Table	   1.5.	   Univariate	   and	   multivariate	   Cox	   regression	   analyses	   to	  
identify	  independent	  predictors	  of	  AKI	  by	  KDIGObin,	  NT0.5	  and	  NT2x.	  	  
AKI	  criteria	  Predictors	   Univariate	   p	   Multivariate	   p	  HR	  (95%	  CI)	   HR	  (95%	  CI)	  
KDIGObin	   	   	   	   	  Age	  (years)	   1.09	  (1.00	  -­‐	  1.02)	   0.143	   	   	  Deoxycholate	  	   1.15	  (0.72	  -­‐	  1.83)	   0.569	   	   	  ICU	  initiation	   1.20	  (0.71	  -­‐	  2.03)	   0.497	   	   	  Leishmaniasis	  	   1.10	  (0.71	  -­‐	  1.70)	   0.679	   	   	  Charlson	  ≥	  4	   1.18	  (0.37	  -­‐	  3.77)	   0.776	   	   	  Furosemide	   1.42	  (0.91	  -­‐	  2.21)	   0.127	   	   	  ACE-­‐I	   1.52	  (0.93	  -­‐	  2.50)	   0.095	   1.53	  (0.92	  -­‐	  2.53)	   0.100	  Polimixin	  B	   0.73	  (0.35	  -­‐	  1.50)	   0.384	   	   	  Vancomycin	   1.16	  (0.77	  -­‐	  1.76)	   0.466	   	   	  Vasopressors	   1.10	  (0.68	  -­‐	  1.80)	   0.693	   	   	  
NT0.5	   	   	   	   	  Age	  (years)	   1.01	  (1.00	  -­‐	  1.02)	   0.104	   1.01	  (1.00	  -­‐	  1.04)	   0.084	  Deoxycholate	  	   1.68	  (0.94	  -­‐	  3.02)	   0.080	   	   	  ICU	  initiation	   1.59	  (0.91	  -­‐	  2.77)	   0.102	   	   	  Leishmaniasis	  	   0.83	  (0.49	  -­‐	  1.41)	   0.833	   	   	  Charlson	  ≥	  4	   1.07	  (0.63	  -­‐	  1.83)	   0.793	   	   	  Furosemide	   1.52	  (0.92	  -­‐	  2.51)	   0.101	   	   	  ACE-­‐I	   1.29	  (0.73	  -­‐	  2.28)	   0.374	   	   	  Polimixin	  B	   0.92	  (0.42	  –	  2.00)	   0.826	   	   	  Vancomycin	   1.70	  (1.07	  -­‐	  2.69)	   0.024	   1.76	  (1.10	  -­‐	  2.78)	   0.018	  Vasopressors	   1.45	  (0.86	  -­‐	  2.45)	   0.162	   	   	  
NT2x	   	   	   	   	  Age	  (years)	   1.00	  (0.98	  -­‐	  1.02)	   0.889	   	   	  Deoxycholate	  	   2.00	  (0.89	  -­‐	  4.48)	   0.092	   	   	  ICU	  initiation	   2.07	  (1.17	  -­‐	  4.01)	   0.031	   	   	  Leishmaniasis	  	   0.51	  (0.24	  -­‐	  1.09)	   0.082	   	   	  Charlson	  ≥	  4	   1.21	  (0.63	  -­‐	  2.34)	   0.571	   	   	  Furosemide	   1.67	  (0.89	  -­‐	  3.14)	   0.112	   	   	  ACE-­‐I	   1.50	  (0.74	  -­‐	  3.02)	   0.261	   	   	  Polimixin	  B	   1.09	  (0.43	  -­‐	  2.77)	   0.853	   	   	  Vancomycin	   2.39	  (1.32	  -­‐	  4.33)	   0.004	   2.00	  (1.08	  -­‐	  3.71)	   0.028	  Vasopressors	   2.58	  (1.41	  -­‐	  4.71)	   0.002	   2.08	  (1.11	  -­‐	  3.91)	   0.022	  Legend:	   Age	   was	   evaluated	   as	   a	   continuous	   variable;	   all	   other	   independent	  variables	   are	   categorical.	   Variables	   with	   p	   <0.20	   in	   univariate	   analyses	   (in	  bold)	  were	   included	  in	  a	  multivariate,	  backward,	  Cox	  regression	  model.	  Only	  the	  variables	  remaining	  at	  the	  final	  model	  are	  shown.	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Table	  1.6.	  Impact	  of	  AKI	  on	  ICU	  admission,	  mechanical	  ventilation	  and	  
inpatient	  mortality.	  	  	  a)	  AKI	  by	  binary	  criteria	  
Outcome	  AKI	  criteria	   AKI	  status	   	  
ICU	  
admission	   No	  AKI	   AKI	   p	  NT2x	   28/117	  (23.9%)	   24/45	  	  (55.6%)	   <0.001	  NT0.5	   22/89	  (24.7%)	   31/73%	  	  (42.5%)	   0.017	  KDIGObin	   20/67	  (29.9%)	   33/95	  	  (34.7%)	   0.514	  
Mechanical	  
ventilation	   No	  AKI	   AKI	   p	  NT2x	   22/117	  (18.8%)	   21/45	  	  (46.7%)	   <0.001	  NT0.5	   16/89	  (18.0%)	   27/73%	  	  (37.0%)	   0.006	  KDIGObin	   15/67	  (22.4%)	   28/95	  	  (29.5%)	   0.314	  
Inpatient	  
mortality	   No	  AKI	   AKI	   p	  NT2x	   25/117	  (21.4%)	   20/45	  	  (44.4%)	   0.003	  NT0.5	   19/89	  (21.3%)	   26/73	  	  (35.6%)	   0.044	  KDIGObin	   16/67	  (23.9%)	   29/95	  	  (30.5%)	   0.352	  
	  b)	  AKI	  by	  KDIGO	  stages	  
	   No	  AKI	   AKI	  stages	  by	  KDIGO	   p	  Variables	   Stage	  1	   Stage	  2	   Stage	  3	  ICU	  admission	   20/67	  (29.9%)	   8/50	  (16.0%)	   12/30	  (40.0%)	   13/15	  (86.7%)	   <0.001	  Mechanical	  ventilation	   15/67	  (22.4%)	   7/50	  (14.0%)	   10/30	  (33.3%)	   11/15	  (73.3%)	   <0.001	  Inpatient	  mortality	   16/67	  (23.9%)	   9/50	  (18.0%)	   9/30	  (30.0%)	   11/15	  (73.3%)	   <0.001	  Legend:	   NT2x	   =	   traditional	   nephrotoxicity	   criteria	   of	   a	   serum	   creatinine	  increase	  ≥	  2x	  over	  baseline;	  NT0.5	  =	   traditional	  nephrotoxicity	  criteria	  of	  an	  absolute	  serum	  creatinine	  increase	  ≥	  0.5	  mg/dl	  over	  baseline;	  KDIGO	  =	  Kidney	  Diseases	  Improving	  Global	  Outcomes;	  a	  KDIGObin	  indicates	  an	  absolute	  serum	  creatinine	  increase	  ≥	  0.3	  mg/dl	  or	  ≥	  1.5x	  over	  baseline.	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On	   univariate	   analyses,	   the	   NT0.5	   criterion	   was	   mildly	   associated	   with	  mortality	   by	   logistic	   regression	  but	  not	   by	  Cox	   regression	   (Table	  1.7).	  When	  AKI	   was	   classified	   using	   the	   KDIGO	   criteria	   as	   a	   binary	   variable,	   it	   became	  significantly	  associated	  with	  mortality	  only	  when	  stages	  2	  and	  3	  (KDIGO	  ≥	  2)	  were	   combined.	   In	   fact,	   when	   looking	   at	   the	   KDIGO	   criteria	   as	   an	   ordinal	  variable,	  mortality	  associated	  with	  stage	  1	  AKI	  (9/52,	  17.3%)	  was	  even	  lower	  than	   in	   those	  without	  AKI	   (16/67,	  23.9%).	  Stage	  3	  AKI	  and	  need	   for	  dialysis	  were	  highly	  associated	  with	  mortality.	  	  
Table	  1.7.	   Impact	  of	  AKI	   criteria	  on	   the	  univariate	  association	  between	  
AKI	  and	  mortality	  	  a)	  Univariate	  logistic	  regression	  
AKI	  criteria	   n/N	  (%)	   OR	  (95%	  CI)	   p	  
Binary	  NT0.5	  NT2x	  KDIGObin	  
	  26/73	  (35.6%)	  20/45	  (44.4%)	  29/95	  (30.5%)	  
	  2.04	  (1.02	  -­‐	  4.09)	  2.94	  (1.41	  -­‐	  6.14)	  1.40	  (0.69	  -­‐	  2.85)	  
	  0.045	  0.004	  0.353	  
KDIGO	  stages	  Stage	  1	  Stage	  2	  Stage	  3	  
	  9/50	  (18.0%)	  9/30	  (30.0%)	  11/15	  (73.3%)	  
	  0.70	  (0.28	  -­‐	  1.75)	  1.37	  (0.52	  -­‐	  3.57)	  8.77	  (2.45	  -­‐	  31.36)	  
	  0.444	  0.525	  0.001	  
Dialysis	   10/11	  (90.9%)	   33.14	  (4.10	  -­‐	  267.98)	   <0.001	  
	   	   	   	  a)	  Univariate	  Cox	  regression	  
AKI	  criteria	   n/N	  (%)	   HR	  (95%	  CI)	   p	  
Binary	  NT0.5	  NT2x	  KDIGObin	  
	  26/73	  (35.6%)	  20/45	  (44.4%)	  29/95	  (30.5%)	  
	  1.53	  (0.84	  -­‐	  2.81)	  2.23	  (1.23	  -­‐	  4.03)	  1.20	  (0.65	  -­‐	  2.24)	  
	  0.168	  0.008	  0.559	  
KDIGO	  stages	  Stage	  1	  Stage	  2	  Stage	  3	  
	  9/50	  (18.0%)	  9/30	  (30.0%)	  11/15	  (73.3%)	  
	  0.62	  (0.26	  -­‐	  1.46)	  1.19	  (0.52	  -­‐	  2.72)	  3.29	  (1.52	  -­‐	  7.13)	  
	  0.270	  0.682	  0.002	  
Dialysis	   10/11	  (90.9%)	   5.05	  (2.47	  -­‐	  10.34)	   <0.001	  Legend:	   NT2x	   =	   traditional	   nephrotoxicity	   criteria	   of	   a	   serum	   creatinine	  increase	  ≥	  2x	  over	  baseline;	  NT0.5	  =	   traditional	  nephrotoxicity	  criteria	  of	  an	  absolute	  serum	  creatinine	  increase	  ≥	  0.5	  mg/dl	  over	  baseline;	  KDIGO	  =	  Kidney	  Diseases	  Improving	  Global	  Outcomes;	  a	  KDIGObin	  indicates	  an	  absolute	  serum	  creatinine	  increase	  ≥	  0.3	  mg/dl	  or	  ≥	  1.5x	  over	  baseline.	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In	  Table	  1.8,	  we	  further	  explored	  the	  association	  between	  AKI	  by	  NT2x	  with	  mortality	  in	  multivariate	  models.	  
Table	  1.8.	  Impact	  of	  AKI	  by	  NT2x	  on	  mortality,	  adjusted	  for	  potential	  
confounders	  a)	  Logistic	  Regression	  Model	  
Model	  Variables	   OR	  (95%	  CI)	   p	  
Unadjusted	  NT2x	   2.94	  (1.41	  -­‐	  6.14)	   0.004	  
Model	  1	  NT2x	  Charlson	  (≥4	  versus	  0-­‐3)	  Steroids	  Vancomycin	  Furosemide	  
	  2.279	  (1.007	  -­‐	  5.16)	  2.694	  (1.104	  -­‐	  6.11)	  2.960	  (1.225	  -­‐	  7.15)	  2.715	  (1.193	  -­‐	  6.18)	  2.597	  (1.104	  -­‐	  6.11)	  
	  0.048	  0.033	  0.019	  0.016	  0.029	  
Model	  2	  NT2x	  Steroids	  Vasopressors	  Mechanical	  ventilation	  
	  1.06	  (0.32	  -­‐	  3.55)	  6.06	  (1.59	  -­‐	  23.02)	  3.60	  (0.99	  -­‐	  13.09)	  44.34	  (12.28	  -­‐	  160.02)	  
	  0.927	  0.008	  0.052	  <0.001	  	  b)	  Cox	  Regression	  Model	  
Model	  	  Variables	   HR	  (95%	  CI)	   p	  
Unadjusted	  NT2x	   	  2.23	  (1.23	  -­‐	  4.03)	   	  0008	  
Model	  1	  NT2x	  Charlson	  (≥4	  versus	  0-­‐3)	  Steroids	  
	  2.31	  (1.27	  -­‐	  4.19)	  2.04	  (1.07	  -­‐	  3.91)	  2.12	  (1.02	  -­‐	  4.42)	  
	  0.006	  0.031	  0.044	  
Model	  2	  NT2x	  Steroids	  Vasopressors	  Mechanical	  ventilation	  
	  1.27	  (0.68	  -­‐	  2.35)	  2.14	  (1.02	  -­‐	  4.47)	  2.20	  (1.02	  -­‐	  4.02)	  5.49	  (2.40	  -­‐	  12.56)	  
	  0.453	  0.044	  0.045	  <0.001	  Legend:	   NT2x	   =	   traditional	   nephrotoxicity	   criteria	   of	   a	   serum	   creatinine	  increase	   ≥	   2x	   over	   baseline.	   Variables	   included	   in	   model	   1:	   First	   block	  (backward)	  Charlson’s	  comorbidity	  index,	  use	  of	  furosemide,	  vancomycin	  and	  steroids;	   second	   block	   (enter)	   AKI	   by	  NT2x.	  Variables	   included	   in	  model	   2:	  First	   block	   (backward)	   all	   variables	   included	   in	   model	   1	   plus	   ICU,	   use	   of	  vasopressors	  and	  mechanical	  ventilation;	  second	  block	  (enter)	  AKI	  by	  NT2x.	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AKI	  remained	  significantly	  associated	  with	  mortality	  even	  when	  adjusted	   for	  the	   Charlson	   comorbidity	   index	   and	   use	   of	   furosemide,	   vancomycin	   and	  steroids	  (Model	  1).	  However,	  when	  use	  of	  vasopressors	  and	  need	  for	  ICU	  and	  mechanical	   ventilation	   were	   included	   (Model	   2),	   AKI	   no	   longer	   predicted	  death.	  	  None	  of	  the	  45	  patients	  with	  a	  diagnosis	  of	  leishmaniasis	  in	  our	  dataset	  ended	  up	  dying	  during	  hospital	  admission.	  Hence,	  this	  variable	  could	  not	  be	  included	  as	   a	   predictor	   in	   multivariate	   mortality	   analyses	   due	   to	   mathematical	  instability	   of	   the	  model.	   Therefore,	  we	   repeated	   all	  multivariate	   logistic	   and	  Cox	   regression	   analyses	   for	   predictors	   of	   mortality	   in	   the	   subset	   of	   117	  patients	  with	   a	  diagnosis	   other	   than	   leishmaniasis	   and	   found	   similar	   results	  (data	  not	  shown).	  	  
DISCUSSION	  	  In	  2001,	  Bellomo	  et	  al	   (22)	  called	  attention	   to	   the	   fact	   that	   there	  were	  more	  than	   30	   different	   definitions	   of	   acute	   renal	   failure	   in	   use	   in	   the	   medical	  literature.	  Their	  call	  for	  a	  consensus	  definition	  of	  this	  syndrome	  was	  answered	  in	  2004,	  with	  the	  publication	  of	  the	  RIFLE	  criteria	  (15).	  Subsequent	  evidence	  that	  minimal	   increases	   in	   SCr	   (as	   small	   as	   0.3	  mg/dl)	  were	   associated	  with	  worse	   outcomes	   (23)	   led	   to	   incorporation	  of	   smaller	   increases	   in	   SCr	   into	   a	  modification	  of	  the	  RIFLE	  criteria	  called	  AKIN	  (16).	  More	  recently,	  the	  KDIGO	  guidelines	  attempted	   to	  harmonize	  earlier	   consensus	  definitions	  and	  staging	  criteria	   for	   AKI	   (17).	   	   Whether	   these	   criteria	   should	   be	   applied	   in	   routine	  clinical	  care	  is	  still	  a	  matter	  of	  debate	  (24).	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Herein,	  we	  showed	  that	  the	  overall	  incidence	  of	  AmB-­‐induced	  AKI	  by	  the	  most	  sensitive	   traditional	   criterion	   (NT	  0.5)	  was	  45.4%	  and	  occurred	  at	  a	  median	  time	  of	  6	  days.	  Newer	  KDIGO	  criteria	  improved	  the	  recognition	  of	  AKI,	  raising	  the	  incidence	  to	  58.6%	  and	  shortening	  the	  median	  time	  to	  detection	  to	  4	  days.	  The	  KDIGO	  criteria	  also	  allowed	  for	  staging	  of	  AKI	  severity.	  Of	  the	  95	  cases	  of	  AKI	  detected	  by	  the	  KDIGO	  criteria,	  52	  (54.7%)	  were	  stage	  1,	  28	  (29.5%)	  were	  stage	  2,	  and	  15	  (15.8%)	  were	  stage	  3;	  11	  of	  the	  15	  stage	  3	  cases	  were	  dialyzed.	  AKI	   occurred	  more	   frequently,	   earlier	   and	   reached	  higher	   stages	   in	   patients	  using	   the	  deoxycholate	  versus	   the	   liposomal	  preparation.	  To	  our	  knowledge,	  this	   is	   the	   first	   study	   to	   evaluate	   the	   performance	   of	   the	   KDIGO	   criteria	   in	  AmB-­‐induced	  AKI.	  	  Since	   the	   incidence	   and	   impact	   of	   AKI	   on	   outcomes	   is	   dependent	   upon	   the	  criteria	  used	  to	  define	  it	  (25),	  we	  sought	  to	  compare	  our	  findings	  with	  that	  of	  prior	   studies	   of	   AmB	   nephrotoxicity.	   In	   those	   studies,	   the	   most	   commonly	  used	  criterion	  to	  define	  renal	  toxicity	  was	  a	  doubling	  (or	  greater)	  of	  baseline	  SCr,	  which	  we	  termed	  NT2x.	  This	  definition	  is	  analogous	  to	  a	  KDIGO	  stage	  2	  or	  greater.	   Applying	   the	   NT2x	   definition	   to	   our	   data,	   the	   incidence	   of	   AKI	  secondary	   to	   deoxycholate	   AmB	   was	   31.7%,	   which	   is	   comparable	   to	   that	  found	  by	  Nucci	  (18),	  Walsh	  (14)	  and	  Johnson	  (20)	  (31.8%,	  33.7%	  and	  37.5%,	  respectively);	   Moreau	   (26)	   and	   Caillot	   (12)	   found	   higher	   (56.3	   and	   66.7%,	  respectively)	  and	  Prentice	  (19)	  encountered	  lower	  (23%)	  incidences.	  For	  the	  liposomal	  preparation,	  we	  detected	  AKI	  by	  NT2x	  criteria	  in	  16.7%	  of	  patients,	  which	   is	   in	   agreement	  with	   the	   findings	   of	  Walsh	   (14)	   (18.7%)	   and	   slightly	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higher	   than	   the	   incidences	   detected	   by	   Leenders	   (27),	   Prentice	   (19)	   and	  Johnson	  (20)(11.8%,	  11.1%	  and	  9.4%,	  respectively).	  Using	  the	  KDIGO	  criteria,	  however,	  we	  detected	  AmB-­‐induced	  AKI	  in	  60.0%	  of	  patients	   using	   deoxycholate	   and	   54.8%	   of	   patients	   using	   liposomal.	   These	  incidences	  are	  significantly	  higher	  than	  those	  previously	  described,	  especially	  for	   the	   liposomal	   preparation.	   In	   fact,	   several	   AKI	   episodes	  must	   have	   gone	  clinically	  undetected	  because	  no	  changes	   in	  management	   in	   response	   to	  AKI	  were	  made	  in	  approximately	  1/3	  of	  patients	  (36/95,	  37.9%)	  and	  a	  Nephrology	  consult	  was	  requested	  in	  less	  than	  1/3	  of	  patients	  with	  AKI	  (25/95,	  26.3%).	  	  Minejima	   et	   al.	   showed	   that	   the	   AKIN	   criteria	   were	   more	   sensitive	   than	  traditional	   criteria	   in	   detecting	   vancomycin	   nephrotoxicity	   (21).	   In	   their	  opinion,	   early	   detection	   of	   vancomycin	   nephrotoxicity	   has	   the	   potential	   to	  improve	  management	  because	  it	  may	  lead	  to	  changes	  in	  management	  that	  halt	  the	   process	   of	   renal	   injury.	   A	   similar	   rationale	   could	   be	   applied	   to	   AmB-­‐induced	   AKI.	   Nevertheless,	   since	   our	   data	   are	   observational,	   prospective	  studies	  would	  be	  needed	  to	  confirm	  this	  hypothesis.	  A	  potential	  drawback	  of	  using	  a	  highly	  sensitive	  AKI	  criterion	  would	  be	  to	  discontinue	  or	  reduce	  AmB	  dose	   unnecessarily,	   potentially	   interfering	   with	   the	   management	   of	   the	  underlying	   infection.	   In	   the	   present	   study,	   KDIGO	   stage	   1	   AKI	   was	   not	  predictive	   of	   need	   for	   ICU	   admission,	   need	   for	   mechanical	   ventilation	   or	  mortality.	   In	   fact,	   these	  outcomes	  were	  numerically	   less	  common	   in	  patients	  with	   stage	   1	   AKI	   than	   in	   those	   without	   AKI.	   When	   AKI	   was	   defined	   by	  traditional	   criteria,	   however,	   there	   was	   a	   significant	   association	   with	   all	   of	  these	  outcomes.	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Independent	   predictors	   of	   AKI	   also	   varied	   according	   to	   the	   definition	   used.	  AKI	  by	  KDIGObin	  was	  predicted	  by	  older	  age	  and	  use	  of	   furosemide	  (logistic	  regression)	  and	  ACE-­‐I	  (Cox	  regression).	  AKI	  by	  NT0.5	  was	  predicted	  by	  use	  of	  older	   age	   and	  use	   of	   vancomycin,	  whereas	   the	  more	   severe	   episodes	   of	   AKI	  defined	   by	   NT2x	   criteria	   were	   predicted	   by	   use	   of	   furosemide	   and	  vasopressors.	  Chertow	  and	  coworkers	  (28)	   identified	   ICU	  admission	  and	  use	  of	  cyclosporine	  as	  independent	  predictors	  of	  AKI.	  In	  our	  study,	  ICU	  admission	  predicted	  AKI	  by	  traditional	  criteria	  on	  univariate	  analysis,	  but	  was	  removed	  from	   the	   model	   after	   adjustment	   for	   other	   confounders.	   We	   did	   not	   have	  patients	  on	  cyclosporine	  for	  comparison.	  Our	  study	  has	  several	  limitations.	  We	  applied	  newer	  diagnostic	  criteria	  for	  AKI	  to	   retrospective	   data.	   Our	   ability	   to	   detect	   AKI	   may	   have	   been	   negatively	  influenced	  by	  the	  fact	  that	  we	  did	  not	  have	  daily	  serum	  creatinine	  values	  for	  all	   patients	   and	   did	   not	   incorporate	   urine	   output	   data.	   Indeed,	   the	   AKIN	  criteria	  could	  not	  be	  applied	  to	  25	  patients	  due	  to	  missing	  creatinine	  values	  at	  critical	  time	  points.	  Although	  we	  did	  not	  have	  formal	  data	  on	  fluid	  responsivity	  or	   renal	   imaging	   for	   all	   patients,	   we	  made	   an	   effort	   to	   exclude	   pre	   or	   post	  renal	  causes	  of	  AKI	  by	  thoroughly	  reviewing	  EMRs	  and	  paper	  charts.	  Finally,	  since	   some	   patients	   were	   exposed	   to	   other	   renal	   insults,	   ischemic	   and/or	  toxic,	  we	  cannot	  state	  that	  use	  of	  AmB	  was	  the	  sole	  cause	  of	  AKI	  in	  all	  subjects.	  	  In	  summary,	  we	  demonstrated	  that	  the	  newer	  AKI	  criteria	  are	  more	  sensitive	  than	   traditional	   criteria	   to	   detect	   AmB-­‐induced	   AKI.	   As	   expected,	   this	  improved	   sensitivity	   occurred	   at	   the	   expense	   of	   potential	   overdiagnosis	   of	  mild	  cases.	  Whether	  or	  not	  this	  increased	  sensitivity	  of	  newer	  AKI	  criteria	  will	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translate	   into	   earlier	   interventions	   and	   better	   renal	   and	   patient	   outcomes	  remains	   unproven.	   In	   our	   dataset,	  mild	   cases	   of	   AKI	  were	   not	   predictive	   of	  worse	   outcomes.	   Potential	   drawbacks	   of	   overly	   sensitive	   AKI	   criteria	   also	  need	  to	  be	  considered	  because	  undue	  AmB	  discontinuation	  or	  dose	  reduction	  could	  compromise	  the	  treatment	  of	  the	  underlying	  disease.	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ABSTRACT	  	  Neutrophil	   Gelatinase-­‐Associated	   Lipocalin	   (NGAL)	   detects	   acute	   kidney	  injury	   (AKI)	   earlier	   than	   serum	   creatinine	   (SCr)	   in	   settings	   such	   as	   cardiac	  surgery,	  contrast	  nephropathy	  and	  intensive	  care	  units.	  We	  hypothesized	  that	  urine	  NGAL	  (UrNGAL)	  would	  be	  an	  early	  biomarker	  of	  drug	  nephrotoxicity.	  To	  test	   this,	   we	   studied	   hemodynamically	   stable	   patients	   treated	   with	  Amphotericin	  B	   (AmB).	  We	  measured	  SCr	  and	  UrNGAL	  at	  baseline	  and	  daily	  after	  initiation	  of	  AmB	  up	  to	  day	  14	  or	  development	  of	  AKI	  by	  SCr	  criteria.	  AKI	  was	   defined	   according	   to	   Kidney	   Diseases	   Improving	   Global	   Outcomes	  (KDIGO)	  criteria	  (increase	  in	  SCr	  by	  ≥0.3	  mg/dl	  within	  48	  hours	  or	  ≥1.5	  times	  baseline	  within	  7	  days).	  We	  studied	  24	  patients	  with	  a	  mean	  age	  of	  48.4	  ±	  16.4	  years.	  Most	  were	  male	  and	  received	  AmB	  (12	  deoxycholate	  and	  12	  liposomal)	  for	   the	   treatment	   of	   leishmaniasis	   (91.7%).	  Overall,	   17/24	  patients	   fullfilled	  KDIGO	  criteria	  for	  AKI.	  Peak	  UrNGAL	  levels	  were	  higher	  in	  AKI	  than	  in	  No	  AKI	  patients	  and	  in	  recipients	  of	  deoxycholate	  than	  liposomal	  AmB.	  The	  diagnostic	  performance	  of	  UrNGAL	  on	  day	  5	   to	  detect	  AKI	  was	  moderate,	  with	   an	  AUC	  0.68	  (95%	  CI	  0.41	  to	  0.95).	   In	  the	  deoxycholate	  subgroup,	  however,	   the	  AUC	  rose	   to	  0.89	  (95%	  CI	  0.67	   to	  1.00).	   In	  a	  patient-­‐level	  analysis,	  we	   found	  that	  UrNGAL	  was	  able	  to	  detect	  AKI	  3.2	  days	  earlier	  than	  SCr	  (3.7	  ±	  2.5	  versus	  6.9	  ±	  3.3	   days,	   time	   to	   AKI	   by	   UrNGAL	   and	   SCr	   criteria,	   respectively;	   p	   =	   0.001).	  Future	   studies	   should	   evaluate	   if	   a	  UrNGAL-­‐oriented	   treatment	   strategy	  will	  improve	  outcomes.	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INTRODUCTION	  	  Acute	   kidney	   injury	   (AKI)	   is	   a	   frequent	   clinical	   syndrome	   in	   hospitalized	  patients	  (1).	  The	  incidence	  of	  AKI	  varies	  widely	  across	  studies,	  mostly	  due	  to	  heterogeneity	   of	   the	   clinical	   settings	   and	   of	   the	   criteria	   used	   to	   define	   the	  syndrome.	  Nevertheless,	  the	  global	  incidence	  of	  AKI	  appears	  to	  be	  increasing	  (2).	   There	   are	  many	   recognized	   etiologies	   of	   AKI	   but	  most	   cases	   are	   due	   to	  ischemic	  and	  /	  or	  toxic	  insults	  (3).	  AKI	  is	  associated	  with	  a	  number	  of	  adverse	  short-­‐term	  outcomes,	   including	  mortality	  (4).	  More	  recently,	  episodes	  of	  AKI	  have	  been	  linked	  to	  development	  of	  chronic	  kidney	  disease	  and	  progression	  of	  chronic	  kidney	  disease	  to	  end-­‐stage	  renal	  disease	  (5).	  	  Several	   interventions	   that	   attenuate	   AKI	   in	   experimental	  models	   have	   been	  proven	   ineffective	   when	   carried	   into	   clinical	   practice	   (6).	   In	   part,	   this	  inefficiency	  has	  been	  attributed	  to	   late	  detection	  of	  AKI,	  after	  the	  occurrence	  of	   irreversible	   acute	   tubular	   necrosis.	   In	   2002,	   a	   panel	   of	   experts	   entitled	  Acute	  Dialysis	  Quality	  Initiative	  began	  efforts	  to	  institute	  a	  uniform	  definition	  of	   AKI	   that	   would	   detect	   the	   syndrome	   at	   an	   earlier	   stage	   (7).	   This	   group	  initially	  published	  the	  RIFLE	  (Risk,	  Injury	  Failure,	  Loss,	  End-­‐stage)	  criteria	  (8)	  that	   were	   later	  modified	   by	   experts	   from	   the	   Acute	   Kidney	   Injury	   Network	  (AKIN)	   into	   the	   so-­‐called	   AKIN	   criteria	   (9).	   More	   recently,	   RIFLE	   and	   AKIN	  were	   consolidated	   into	   the	   Kidney	   Diseases	   Improving	   Global	   Outcomes	  (KDIGO)	   criteria	   (10).	   According	   to	   KDIGO,	   AKI	   is	   defined	   as	   an	   increase	   in	  serum	  creatinine	  (SCr)	  by	  ≥	  0.3	  mg/dl	  within	  48	  hours;	  or	  an	  increase	  in	  SCr	  to	  ≥	  1.5x	  baseline,	  which	   is	  known	  or	  presumed	  to	  have	  occurred	  within	  the	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prior	   7	   days;	   or	   urine	   volume	   <	   0.5	   ml/kg/hour	   for	   6	   hours	   (11).	   In	   a	  retrospective	  cohort	  study	  of	  2579	  critically	  ill	  patients,	  KDIGO	  outperformed	  AKIN	   criteria,	   showing	   improved	   sensitivity	   to	   detect	   AKI	   without	  compromising	  specificity	  (12).	  	  Nevertheless,	   as	   it	   relies	  on	  SCr	  and	  urine	  volume,	   the	  KDIGO	  criteria	  might	  still	   have	   several	   limitations.	   Adequate	   measurement	   of	   urine	   volume,	   for	  example,	   may	   not	   occur	   without	   a	   bladder	   catheter,	   especially	   outside	   the	  intensive	  care	  setting.	  Additionally,	   a	   significant	  proportion	  of	  AKIs	  are	  non-­‐oliguric.	   Finally,	   the	   use	   of	   loop	   diuretics	  may	   invalidate	   urine	   volume	   as	   a	  marker	   of	  AKI.	   SCr	   also	   has	   significant	   restrictions	   because	   its	   levels	   can	  be	  affected	   by	   factors	   unrelated	   to	   the	   glomerular	   filtration	   rate,	   such	   as	  catabolism,	   rhabdomyolysis,	   certain	   antibiotics,	   hemodilution	   and	   muscle	  mass.	   In	   addition,	   a	   rise	   in	   SCr	   requires	   a	   significant	  decrease	   in	   glomerular	  filtration	  rate	  and	  is	  thus	  considered	  a	  late	  marker	  for	  AKI.	  In	  the	  last	  decade,	  there	  has	  been	  an	  intense	  search	  for	  early	  biomarkers	  of	  AKI	  (13).	  In	  humans,	  the	   AKI	   biomarker	   that	   has	   been	   most	   studied	   is	   neutrophil	   gelatinase–associated	  lipocalin	  (NGAL)	  (14).	  	  NGAL	  is	  a	  member	  of	  the	  lipocalin	  superfamily.	  These	  proteins	  are	  composed	  of	   8	   β-­‐strands	   that	   form	   a	   β-­‐barrel	   encircling	   a	   calyx.	   In	   2003,	  Mishra	   et	   al.	  demonstrated	   that	  NGAL	  protein	   is	  markedly	  overexpressed	   in	   the	  proximal	  tubules	   of	   early	   ischemic	   mouse	   kidneys.	   More	   importantly,	   NGAL	   protein	  could	  be	  easily	  detected	  in	  the	  urine	  immediately	  after	  mild	  renal	  ischemia	  in	  mice;	   this	   was	   also	   reproduced	   in	   rats	   and	   in	   a	   model	   of	   nephrotoxic	  (cisplatin)	  kidney	   injury	  (15).	   In	  2005,	   the	  same	  group	  of	   investigators	  were	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able	  to	  show	  that	   in	  children	  submitted	  to	  cardiopulmonary	  bypass,	  urine	  or	  serum	  NGAL	  levels	  two	  hours	  after	  surgery	  were	  able	  to	  predict	  those	  patients	  who	  would	   go	   on	   to	   develop	   AKI	   by	   SCr	   criteria	   (16).	   Although	   the	   role	   of	  NGAL	   overexpression	   following	   tubular	   injury	   is	   not	   completely	   elucidated,	  there	   is	   some	   evidence	   that	   it	   might	   be	   protective	   (17)	   by	   aiding	   the	   cell	  proliferation-­‐repair	  process	  (18).	  	  Most	   NGAL	   studies	   in	   humans	   have	   been	   performed	   in	   the	   context	   of	   large	  surgeries	   (16,	   19,	   20),	   contrast	   nephropathy	   (21–25)	   and	   in	   critically	   ill	  patients	   (26–29);	   collectively,	   they	   suggest	   that	   NGAL	   is	   a	   promising	   early	  biomarker	  of	  AKI.	  However,	   there	  are	  no	   intervention	  studies	  demonstrating	  that	  the	  early	  detection	  of	  renal	  damage	  in	  these	  situations	  results	  in	  reduced	  incidence	  of	   clinically	  manifest	  AKI	  or	   in	  associated	  morbidity	  and	  mortality	  (30).	  In	  fact,	  early	  detection	  of	  kidney	  injury	  after	  a	  single,	  isolated	  insult,	  such	  as	   after	  heart	   surgery	  or	   a	   single	  dose	  of	   iodinated	   contrast,	  may	  have	   little	  practical	  value,	  because	  the	  full	  insult	  has	  already	  occurred.	  In	  sepsis	  or	  septic	  shock,	  although	  insults	  are	  ongoing,	  early	  recognition	  of	  AKI	  may	  not	  translate	  into	  better	  management	  if	   the	  physician	  is	  already	  doing	  everything	  possible	  to	   reverse	   the	   hemodynamic	   abnormalities	   that	   are	   causing	   kidney	   damage.	  Furthermore,	  the	  inflammatory	  environment	  of	  sepsis	  may	  interfere	  with	  the	  diagnostic	  performance	  of	  NGAL,	  as	  it	  may	  increase	  regardless	  of	  renal	  injury	  (31–34).	  	  One	  promising	  application	  for	  biomarkers	  of	  AKI,	  however,	  is	  monitoring	  drug	  nephrotoxicity	   (35–37).	   Once	   a	   nephrotoxic	   insult	   causes	   irreversible	   acute	  tubular	   necrosis,	   it	   usually	   takes	   7	   to	   21	   days	   for	   renal	   function	   to	   recover,	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even	  after	   the	  offending	  agent	   is	   stopped.	   In	   this	   setting,	  early	  knowledge	  of	  ongoing	  AKI	  may	   enable	   the	   physician	   to	   take	  measures	   to	   avoid	   additional	  damage	   before	   the	   progression	   to	   full	   blown	   acute	   tubular	   necrosis.	  Preliminary	   studies	   in	   rodents	   have	   shown	   that	   NGAL	   is	   a	   promising	  biomarker	  of	  AKI	  secondary	  to	  cisplatin	  (15,	  38),	  amphotericin	  B	  (AmB)	  (39),	  colistin	   (40)	   and	   gentamicin	   (41),	   but	   few	   studies	   have	   explored	   this	  application	  in	  humans.	  	  In	   12	   patients	   with	   cancer	   receiving	   cisplatin	   infusion,	   urinary	   NGAL	  (UrNGAL)	  rose	  4.5	  days	  earlier	   than	   the	  peak	  SCr	  (42).	  However,	   in	  patients	  with	   acute	   bacterial	   infections,	   the	   ability	   of	   plasma	   NGAL	   and	   UrNGAL	   to	  predict	  the	  nephrotoxicity	  of	  vancomycin	  (43)	  and	  colistin	  (44),	  respectively,	  was	  compromised.	  	  Aiming	  to	  evaluate	  the	  role	  of	  UrNGAL	  as	  an	  early	  biomarker	  of	  drug-­‐induced	  AKI,	   we	   used	   the	   treatment	   of	   non-­‐septic,	   hemodynamically	   stable	   patients	  with	   AmB	   as	   a	   unique	   model.	   At	   our	   institution,	   leishmaniasis	   is	   the	   main	  indication	   for	   AmB	   on	   the	   hospital	   wards.	   These	   patients	   usually	   do	   not	  present	  with	   an	   inflammatory	   response	   syndrome	   or	   renal	   dysfunction,	   are	  hemodynamically	   stable	   (and	   hence	   not	   subject	   to	   ischemic	   insults)	   and	  require	  in-­‐house	  treatment	  with	  AmB	  for	  prolonged	  periods.	  AmB	  is	  a	  highly	  nephrotoxic	  drug	  with	  antiparasitic	  and	  antifungal	  properties.	  A	  recent	  meta-­‐analysis	   indicated	   that	   32.5%	   of	   patients	   treated	   with	   the	   deoxycholate	  formulation	   and	   14.5%	   treated	  with	   the	   liposomal	   formulation	   develop	   AKI	  (45).	  However,	  these	  average	  incidences	  of	  AKI	  reported	  in	  this	  meta-­‐analysis	  came	   from	   studies	   conducted	   more	   than	   10	   years	   ago,	   involving	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heterogeneous	   populations	   and	   using	   various	   definitions	   of	   AKI.	   More	  importantly,	  none	  of	   them	  used	  currently	  accepted	  AKI	  criteria.	  Unpublished	  data	  from	  a	  retrospective	  cohort	  study	  by	  our	  group,	  that	   included	  162	  (120	  deoxycholate	   and	   42	   liposomal)	   inpatients	   treated	   with	   AmB,	   revealed	   an	  overall	   incidence	  of	  AKI	  of	  58.6%	  when	  using	   the	  KDIGO	  criteria.	  Moreover,	  KDIGO	   criteria	   detected	   AmB-­‐induced	   AKI	   earlier	   than	   traditional	   criteria.	  Kondo	   et	   al.	   have	   shown	   that	   the	   genes	   for	   NGAL	   are	   upregulated	   after	  treatment	  with	  AmB	  (39)	  but	  to	  date,	  there	  are	  no	  human	  studies	  evaluating	  the	  role	  of	  NGAL	  as	  an	  early	  biomarker	  of	  AmB	  nephrotoxicity.	  	  
MATERIALS	  AND	  METHODS	  	  
Site:	  Hospital	   Professor	  Edgard	   Santos,	   a	   tertiary	   care	   facility	   affiliated	  with	  the	   Medical	   School	   of	   the	   Federal	   University	   of	   Bahia,	   located	   in	   Salvador,	  Bahia,	  Brazil.	  
Population:	  All	  adult	  inpatients	  initiating	  treatment	  with	  AmB	  in	  the	  medical	  wards	  were	  considered	  potentially	  eligible.	  We	  did	  not	  include	  intensive	  care	  unit	  patients,	  as	  they	  are	  usually	  exposed	  to	  ischemic	  renal	  insults	  due	  to	  septic	  or	  cardiogenic	  shock.	  Participants	  with	  urinary	  tract	  infection,	  status	  post-­‐renal	  transplantation,	  with	  ongoing	  acute	  kidney	  injury,	  advanced	  (stage	  IV	  or	  stage	  V)	  chronic	  kidney	  disease,	  and	  who	  used	  AmB	  for	  less	  than	  3	  days	  were	  excluded.	  
Design:	   prospective	   cohort	   study	   of	   adult	   inpatients	   treated	   with	   AmB.	   All	  patients	   were	   followed	   from	   initiation	   of	   AmB	   until	   death	   or	   hospital	  discharge.	   From	   the	   viewpoint	   of	   treatment,	   the	   study	   was	   observational,	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without	  any	  deviation	  from	  standard	  practice.	  The	  indication	  for	  treatment	  as	  well	  as	  the	  dose	  and	  type	  of	  AmB	  were	  the	  responsibility	  of	  the	  medical	  staff	  assisting	   the	   patient,	   without	   any	   interference	   from	   the	   research	   team.	  Similarly,	   decisions	   to	   discontinue	   or	   reduce	   the	   dose	   of	   AmB	   were	  prerogatives	   of	   the	   primary	   care	   team.	   Our	   intervention	   was	   purely	  diagnostic.	  Blood	  and	  urine	  samples	  were	  collected	  prior	  to	  initiation	  of	  AmB	  therapy	  and	  daily	  thereafter	  until	  day	  14	  or	  development	  of	  AKI	  by	  SCr	  criteria	  using	   the	   KDIGO	   definition.	   The	   primary	   care	   team	   had	   no	   knowledge	   of	  UrNGAL	  levels	  because	  testing	  was	  done	  in	  batches	  at	  a	  later	  point	  in	  time.	  	  
Protection	   of	   human	   subjects:	   Our	   hospital’s	   institutional	   review	   board	  approved	   the	   study	   (protocol	   number	   08087412.1.0000.0049)	   and	   all	  participants	  provided	  written	  informed	  consent.	  
Measurements:	   We	   collected	   data	   on	   demographics,	   date	   of	   admission,	  indication	   for	   AmB	   use,	   type	   and	   dose	   of	   AmB,	   comorbid	   conditions,	   use	   of	  other	   potentially	   nephrotoxic	   drugs,	   and	   daily	   blood	   and	   urine	   samples	   for	  laboratory	  data.	  	  
Laboratory	   methods:	   Blood	   samples	  were	   collected	   in	   the	  morning	   by	   the	  hospital’s	   laboratory	   personnel	   through	   peripheral	   venipuncture	   and	   sent	  immediately	  to	  our	  hospital’s	  clinical	  laboratory	  for	  analysis	  of	  SCr,	  potassium,	  magnesium	   and	   bicarbonate,	   according	   to	   the	   usual	   routine	   for	   inpatients.	  Twenty	   ml	   of	   freshly	   voided	   urine	   was	   collected	   in	   the	   morning	   by	   the	  research	   team;	   ten	  ml	  was	   sent	   to	   the	   hospital	   clinical	   laboratory	   for	   urine	  creatinine	  and	  the	  remaining	  ten	  ml	  was	  immediately	  stored	  in	  a	  -­‐80oC	  freezer	  (SANYO	   Vip	   Series).	   Frozen	   urine	   samples	   were	   shipped	   on	   dry	   ice	   to	   a	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commercial	   laboratory	  (Science	  Pro	  laboratories,	  São	  Caetano	  do	  Sul,	  Brazil).	  Urine	   samples	  were	   centrifuged	   and	   supernatants	   diluted	   1/50	   for	   UrNGAL	  measurement	   using	   NGAL	   Rapid	   ELISA	   Kit	   (catalog	   number	   KIT037RUO)	  according	   to	   manufacturer’s	   instructions	   (BioPorto	   Diagnostics,	   Gentofte,	  Denmark).	   Each	   subject’s	   longitudinal	   samples	   were	   assayed	   in	   the	   same	  batch.	  Quantitative	  UrNGAL	  results	  were	  obtained	  in	  ng/ml	  (assay	  range	  0.2-­‐20.0	  ng/ml,	  limit	  of	  detection	  <	  0.1	  ng/ml).	  	  
AmB	   treatment	   regimen:	   At	   our	   hospital,	   the	   usual	   protocol	   for	   initiating	  deoxycholate	  AmB	  is	  to	  start	  with	  0.25	  mg/kg/d	  and	  increase	  5-­‐10	  mg/day	  to	  a	  maximum	  of	  1.5	  mg/kg/d.	  For	  the	  liposomal	  preparation,	  we	  start	  with	  3-­‐5	  mg/kg/d.	   Both	   are	   diluted	   in	   500	   ml	   of	   5%	   dextrose	   in	   water	   and	   infused	  intravenously	  over	  1-­‐2	  hours.	  In	  addition,	  patients	  receive	  500	  to	  2000	  ml	  of	  0.9%	   NaCl	   over	   24	   hours,	   at	   the	   discretion	   of	   the	   attending	   physician.	  	  Pretreatment	   with	   acetaminophen,	   anti-­‐histamines	   or	   hydrocortisone	   is	  reserved	  for	  patients	  who	  develop	  reactions	  during	  infusion.	  	  
Definitions:	  AKI	  was	  defined	  according	  to	  the	  KDIGO	  criteria,	  which	  requires	  an	  absolute	  increase	  in	  SCr	  by	  ≥	  0.3	  mg/dl	  within	  48	  hours;	  or	  an	  increase	  in	  SCr	  to	  ≥	  1.5x	  baseline,	  which	  is	  known	  or	  presumed	  to	  have	  occurred	  within	  the	   prior	   7	   days	   (binary	   definition,	   hereafter	   abbreviated	   as	   KDIGObin,	  equivalent	   to	   KDIGO	   stage	   1	   or	   greater).	   We	   did	   not	   have	   rigorous	  measurement	   of	   urine	   volume.	   AKI	  was	   staged	   according	   to	   KDIGO:	   stage	   1	  when	  there	  was	  absolute	  increase	  in	  SCr	  ≥	  0.3	  mg/dl	  or	  an	  increase	  in	  SCr	  1.5-­‐1.9x	  baseline;	  stage	  2	  required	  an	  increase	  in	  SCr	  2.0-­‐2.9x	  baseline	  and	  stage	  3	  an	  increase	  in	  SCr	  to	  ≥	  3.0x	  baseline	  or	  initiation	  of	  dialysis.	  For	  comparison,	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we	   examined	   two	   definitions	   of	   AmB	   nephrotoxicity	   commonly	   used	   in	   the	  literature:	  an	  absolute	  increase	  in	  SCr	  by	  ≥	  0.5	  mg/dl	  (NT0.5)	  and	  doubling	  of	  baseline	  SCr	  (NT2x),	  the	  latter	  being	  equivalent	  to	  a	  KDIGO	  stage	  2	  or	  greater.	  There	  is	  currently	  no	  consensus	  definition	  of	  AKI	  based	  on	  UrNGAL	  levels.	  	  
Outcomes:	   The	   primary	   endpoint	   was	   the	   difference	   between	   the	   average	  time	   to	   detection	   of	   AKI	   by	   SCr	   criteria	   (KDIGO)	   versus	   empirically-­‐derived	  UrNGAL	   criteria.	   We	   also	   evaluated	   the	   sensitivity,	   specificity,	   positive	   and	  negative	  predictive	  value	  and	  accuracy	  of	  UrNGAL	   for	   the	  detection	  of	  AmB-­‐induced	  AKI.	  	  
Statistical	   analyses:	   Data	  were	   summarized	   by	   counts,	   relative	   frequencies	  and	  measures	  of	  central	  tendency	  and	  dispersion	  (mean	  ±	  standard	  deviation	  or	  median	  and	  interquartile	  range,	  according	  to	  the	  shape	  of	  the	  distribution).	  NGAL	   data	   were	   analyzed	   in	   ng/ml	   and	   μg/g	   of	   urine	   creatinine.	   Given	   the	  asymmetry	   of	   UrNGAL	   data,	   we	   also	   analyzed	   log-­‐transformed	   data.	   To	  account	   for	   differences	   in	   baseline	   values,	   we	   also	   expressed	   UrNGAL	   as	   a	  relative	  value,	  by	  dividing	  values	  from	  days	  1	  thru	  14	  by	  the	  baseline	  (day	  0)	  value.	   Correlation	   between	   datapoints	   was	   assessed	   with	   the	   Spearman’s	  correlation	   coeficient.	   Comparisons	   of	   continuous	   variables	   between	   two	  groups	  were	  made	  with	   the	  Wilcoxon	   rank-­‐sum	   test	   or,	   for	   log-­‐transformed	  UrNGAL	   data,	   the	   Student’s	   t	   test.	   Trend	   across	   ordered	   groups	   was	   tested	  using	  a	  nonparametric	  test	  developed	  by	  Cuzick,	  which	  is	  an	  extension	  of	  the	  Wilcoxon	  rank-­‐sum	  test.	  Receiver	  operating	  characteristics	  (ROC)	  curves	  were	  generated	   at	   all	   time-­‐points	   to	   determine	   the	   best	   sensitivity/specificity	  cutoffs	   for	   the	  detection	  of	  AKI	  by	  UrNGAL.	   Individual	  patient-­‐level	   analyses	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were	  also	  carefully	  conducted	  to	  identify	  the	  best	  UrNGAL	  cutoff	  for	  the	  early	  diagnosis	   of	   AKI.	   Two	   by	   two	   tables	   were	   constructed	   and	   sensitivity,	  specificity,	   positive	   and	   negative	   predictive	   values	   and	   accuracy	   were	  determined.	   Time	   to	   peak	  UrNGAL	   versus	   time	   to	   peak	   SCr	   in	   patients	  with	  AKI	   and	   time	   to	   AKI	   by	   empirically-­‐derived	   UrNGAL	   criteria	   versus	   time	   to	  AKI	   by	   SCr	   (KDIGO)	   criteria	   in	   matched	   pairs	   of	   concordant	   cases	   (true	  positives)	  were	  compared	  with	  the	  one-­‐sample	  paired	  t	  test.	  A	  p	  value	  <	  0.05	  in	   final	   analyses	   was	   considered	   statistically	   significant.	   All	   analyses	   were	  performed	  using	  the	  Stata	  12.1	  and	  IBM	  SPSS	  Statistics	  20.0	  softwares.	  	  
Sample	   size:	   The	   minimum	   sample	   size	   required	   to	   detect	   a	   difference	  between	  mean	  time	  to	  AKI	  by	  UrNGAL	  criteria	  and	  mean	  time	  to	  AKI	  by	  SCr	  (KDIGO)	   criteria	   was	   calculated	   using	   Open	   Epi,	   available	   at	  http://www.openepi.com/v37/SampleSize/SSMean.htmTh.	   A	   priori	   sample	  size	  calculation	  was	  based	  on	  the	  following	  assumptions:	  mean	  time	  to	  AKI	  by	  UrNGAL	  criteria	  of	  3	  ±	  1	  days	  and	  mean	  time	   to	  AKI	  by	  SCr	  criteria	  of	  5	  ±	  2	  days.	  A	  sample	  size	  of	  20	  AKI	  cases	  would	  provide	  us	  80%	  power	  to	  detect	  an	  average	  difference	  of	  2	  days	  with	  an	  alpha	  level	  of	  0.05.	  	  
RESULTS	  	  
Study	  population	  	  We	  studied	  24	  patients,	  with	  a	  mean	  age	  of	  48.4	  ±	  16.4	  years.	  Most	  were	  male,	  from	   rural	   areas	   and	   received	   AmB	   (12	   deoxycholate	   and	   12	   liposomal)	  predominantly	  for	  the	  treatment	  of	  leishmaniasis	  (91.7%).	  Three	  patients	  had	  HIV.	  Mean	   length	   of	   stay	   in	   the	   hospital	  was	   slightly	   over	   one	  month.	  Mean	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baseline	  renal	  function,	  acid-­‐base	  status	  and	  electrolytes	  were	  within	  normal	  limits	  (Table	  2.1).	  	  At	  baseline,	  UrNGAL	  levels	  were	  low	  in	  the	  majority	  of	  patients	  with	  a	  median	  [IQR]	  of	  0.23	  [0.11	  to	  0.93]	  ng/ml;	  in	  6	  patients,	  baseline	  UrNGAL	  was	  above	  1.0	  ng/ml;	   one	  of	   them	  had	  a	  baseline	   level	   of	  13.9	  ng/ml	   in	   the	   absence	  of	  clinically	   manifest	   AKI.	   Due	   to	   the	   skewness	   of	   UrNGAL	   data,	   we	   also	  performed	  log	  transformation	  (Table	  2.1).	  	  
Summary	  of	  AmB	  treatment	  	  For	  deoxycholate	  AmB,	  the	  mean	  starting,	  maintenance	  and	  total	  doses	  were	  26	  ±	  10	  mg	  (min.	  15	  mg/d;	  max.	  50	  mg/d),	  47	  ±	  18	  mg	  (min.	  15	  mg/d;	  max.	  75	  mg/d),	  and	  730	  ±	  731	  mg,	  respectively	  (min.	  75	  mg/d;	  max.	  2485	  mg/d).	  For	  liposomal	  AmB,	  the	  mean	  starting,	  maintenance	  and	  total	  doses	  were	  116	  ±	  38	  mg	   (min.	   50	  mg/d;	  max.	   150	  mg/d),	   211	  ±	  85	  mg	   (min.	   50	  mg/d;	  max.	   300	  mg/d)	  and	  2560	  ±	  1314	  mg,	  respectively	  (min.	  450	  mg/d;	  max.	  5250	  mg/d).	  	  
Incidence	  and	  time	  to	  AKI	  by	  SCr	  criteria	  	  We	  sought	  to	  establish	  the	  most	  sensitive	  SCr-­‐based	  criteria	  for	  AKI.	  First,	  we	  examined	   two	   traditional	   definitions	   of	   nephrotoxicity.	   By	   NT2x	   criterion,	  4/24	   (16.7%)	   patients	   developed	   AKI	   (3/12	   deoxycholate	   and	   1/12	  liposomal)	   10.3	   ±	   3.4	   days	   after	   initiating	   AmB.	   Peak	   SCr	   in	   those	   who	  developed	   AKI	   by	  NT2x	   criterion	  was	   1.8	   ±	   0.4	  mg/dl,	   occurring	   10.8	   ±	   2.6	  days	  after	  initiation	  of	  AmB.	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Table	  2.1.	  Demographic,	  clinical	  and	  baseline	  laboratory	  variables	  in	  24	  
patients	  treated	  with	  AmB.	  
Variables	   All	  (n	  =	  24)	  
Age	  (years),	  mean±SD	   48.4	  ±	  16.4	  
Gender	  Male	  Female	   	  19/24	  (79.0%)	  5/24	  (21.0%)	  
Place	  of	  residence	  Salvador	  (capital)	  Rural	  areas	   	  3/24	  (12.5%)	  21/24	  (87.5%)	  
Reason	  for	  AmB	  treatment	  Leishmaniasis*	  Histoplasmosis	  Paracoccidioidomycosis	  
	  22/24	  (91.7%)	  1/24	  (4.17%)	  1/24	  (4.17%)	  
Significant	  comorbidities	  HIV	  Systemic	  lupus	  erythematosus	  Hemophagocytic	  syndrome	  Cirrhosis	  
	  3/24	  (12.5%)	  1/24	  (4.17%)	  1/24	  (4.17%)	  1/24	  	  (4.17%)	  
AmB	  formulation	  Deoxycholate	  Liposomal	   	  12/24	  (50.0%)	  12/24	  (50.0%)	  
Length	  of	  stay	  in	  the	  hospital	  (days),	  mean±SD	   36.2	  ±	  15.4	  	  
Baseline	  serum	  laboratory	  values	  Serum	  creatinine	  (mg/dl)	  Serum	  potassium	  (meq/l)	  Serum	  magnesium	  (mg/dl)	  Serum	  bicarbonate	  (meq/l	  
	  0.8	  ±	  0.2	  4.3	  ±	  0.6	  2.0	  ±	  0.3	  28.0	  ±	  4.8	  
Baseline	  urine	  laboratory	  values	  Urine	  creatinine	  (mg/dl),	  n	  =	  24	   	  102.2	  ±	  69.2	  
Baseline	  UrNGAL	  strata	  	  0.01	  |–	  1.00	  ng/ml	  1.00	  |–	  2.00	  ng/ml	  ≥	  2.00	  ng/ml	  
	  18/24	  (75.0%)	  3/24	  (12.5%)	  3/24	  (12.5%)	  
Baseline	  UrNGAL	  UrNGAL	  (ng/ml)	  Log	  UrNGAL	  (ng/ml)	  UrNGAL	  (μg/g	  creatinine)	  Log	  UrNGAL	  (μg/g	  creatinine)	  
	  1.2	  ±	  2.9	  -­‐1.2	  ±	  1.7	  3.1	  ±	  11.0	  -­‐1.1	  ±	  1.9	  Legend:	   AmB	   =	   amphotericin	   B;	   UrNGAL	   =	   urine	   neutrophil	   gelatinase-­‐associated	   lipocalin.	   *Of	   the	   22	   cases	   of	   leishmaniasis,	   5	   were	   visceral	  (kalazar)	   and	   17	   were	   tegumentary	   (localized	   cutaneous	   leishmaniasis	   =	   2;	  disseminated	   cutaneous	   leishmaniasis	   =	   6;	   mucosal	   leishmaniasis	   =	   3;	  disseminated	  cutaneous	  leishmaniasis	  with	  mucosal	  involvement	  =	  6)	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Using	  NT0.5	   criterion,	  we	  were	   able	   to	  diagnose	  11	  additional	   cases,	   raising	  the	   incidence	   of	   AKI	   to	   62.5%	   (15/24),	   9/12	   deoxycholate	   and	   6/12	  liposomal,	  and	  reducing	  time	  to	  detection	  to	  8.0	  ±	  3.4	  days.	  Peak	  SCr	  in	  those	  who	  developed	  AKI	   by	  NT0.5	  was	   1.7	   ±	   0.4	  mg/dl,	   occurring	   8.3	   ±	   3.5	   days	  after	  initiation	  of	  AmB.	  
Table	  2.2.	   Incidence	  of	  AKI	   according	   to	  different	  definitions,	   stratified	  
by	  type	  of	  AmB.	  
	   All	  
(n	  =	  24)	  
Type	  of	  AmB	  
AKI	  criteria	   Deoxycholate	  
(n	  =	  12)	  
Liposomal	  
(n	  =	  12)	  
Binary	   	   	   	  NT2x	   4/24	  (16.7%)	   3/12	  (25.0%)	   1/12	  (8.3%)	  NT0.5	   15/24	  (62.5%)	   9/12	  (75.0%)	   6/12	  (50.0%)	  KDIGO	   17/24	  (70.8%)	   10/12	  (83.3%)	   7/12	  (58.3%)	  
KDIGO	  stages	   	   	   	  Stage	  1	   13/24	  (54.2%)	   8/12	  (66.7%)	   6/12	  (50.0%)	  Stage	  2	   4/24	  (16.7%)	   3/12	  (25.0%)	   1/12	  (8.3%)	  Stage	  3	   0/24	  (0.0%)	   0/12	  (0.0%)	   0/12	  (0.0%)	  Legend:	   AmB	   =	   Amphotericin	   B.	   NT2x	   =	   traditional	   nephrotoxicity	   criterion	  that	   requires	  at	   least	  doubling	  of	   the	  SCr.	  NT0.5	  =	   traditional	  nephrotoxicity	  criterion	  that	  requires	  an	  absolute	  increase	  in	  SCr	  of	  at	  least	  0.5	  mg/dl.	  KDIGO	  =	   kidney	   diseases	   improving	   global	   outcomes	   criterion	   that	   requires	   an	  increase	  in	  SCr	  by	  ≥	  0.3	  mg/dl	  within	  48	  hours;	  or	  an	  increase	  in	  SCr	  to	  ≥	  1.5x	  baseline,	   which	   is	   known	   or	   presumed	   to	   have	   occurred	  within	   the	   prior	   7	  days.	  A	  KDIGO	  stage	  1	  required	  an	  increase	  in	  SCr	  by	  ≥	  0.3	  mg/dl	  or	  1.5-­‐1.9x	  baseline;	  stage	  2	  required	  an	  increase	  in	  SCr	  2.0-­‐2.9x	  baseline	  and	  stage	  3	  an	  increase	  in	  SCr	  to	  ≥	  3.0x	  baseline	  or	  initiation	  of	  dialysis.	  	  	  Finally,	  using	  the	  KDIGObin	  criterion,	  we	  detected	  17/24	  (70.8%)	  cases	  of	  AKI,	  10/12	  deoxycholate	  and	  7/12	   liposomal,	   reducing	   time	   to	  detection	   to	  7.2	  ±	  3.1	   days.	   Peak	   SCr	   in	   those	  who	   developed	   AKI	   by	   KDIGObin	  was	   1.6	   ±	   0.4	  mg/dl,	   occurring	  8.2	  ±	  3.4	  days	   after	   initiation	  of	  AmB	   (Tables	  2.2	   and	  2.3).	  AKI	  and	  peak	  SCr	  occurred	  earlier	   in	   the	  deoxycholate	   than	   in	   the	   liposomal	  group,	  regardless	  of	  the	  criteria	  used.	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Table	   2.3.	   Time	   to	   AKI	   and	   time	   to	   peak	   SCr	   and	   peak	   UrNGAL	   in	   AKI	  
patients	   according	   to	   different	   definitions,	   stratified	   by	   type	   of	   AmB	  
preparation.	  
AKI	  criteria	   All	   Type	  of	  AmB	  Deoxycholate	   Liposomal	  
Time	  to	  AKI,	  days	   	   	   	  NT2x	   10.3	  ±	  3.4	  (n=4)	   9.3	  ±	  3.5	  (n=3)	   13.0	  (n=1)	  NT0.5	   8.0	  ±	  3.4	  (n=15)	   7.3	  ±	  3.5	  (n=9)	   9.0	  ±	  3.4	  (n=6)	  KDIGO	   7.2	  ±	  3.1	  (n=17)	   7.1	  ±	  3.6	  (n=10)	   7.3	  ±	  2.6	  (n=7)	  UrNGAL	  ≥	  2.54	  ng/ml*	   5.1	  ±	  3.6	  (n=11)	   5.5	  ±	  3.5	  (n=8)	   4.0	  ±	  4.4	  (n=3)	  UrNGAL	  ≥	  3x	  baseline*	   3.7	  ±	  2.5	  (n=13)	   3.5	  ±	  2.2	  (n=10)	   4.3	  ±	  4.0	  (n=3)	  
Time	  to	  peak,	  days	   	   	   	  SCr,	  NT2x	   10.8	  ±	  2.6	  (n=4)	   10.0	  ±	  2.7	  (n=3)	   13.0	  (n=1)	  SCr,	  NT0.5	   8.3	  ±	  3.5	  (n=15)	   7.8	  ±	  3.5	  (n=9)	   9.2	  ±	  3.6	  (n=6)	  SCr,	  KDIGO	   8.2	  ±	  3.4	  (n=17)	   8.0	  ±	  3.4	  (n=10)	   8.6	  ±	  3.7	  (n=7)	  UrNGAL,	  ng/ml	   6.8	  ±	  3.3	  (n=17)	   6.3	  ±	  3.5	  (n=10)	   7.4	  ±	  3.2	  (n=7)	  UrNGAL,	  %	  change	  	   6.8	  ±	  3.3	  (n=17)	   6.3	  ±	  3.5	  (n=10)	   7.4	  ±	  3.2	  (n=7)	  Legend:	  data	  expressed	  as	  mean	  ±	  standard	  deviation.	  AmB	  =	  Amphotericin	  B.	  NT2x	  =	  traditional	  nephrotoxicity	  criterion	  that	  requires	  at	  least	  doubling	  of	  the	  SCr.	  NT0.5	  =	   traditional	  nephrotoxicity	  criterion	   that	   requires	  an	  absolute	   increase	   in	  SCr	  of	  at	  least	   0.5	  mg/dl.	  KDIGO	  =	   kidney	  diseases	   improving	   global	   outcomes	   criterion	   that	  requires	  an	  increase	  in	  SCr	  by	  ≥	  0.3	  mg/dl	  within	  48	  hours;	  or	  an	  increase	  in	  SCr	  to	  ≥	  1.5x	  baseline,	  which	  is	  known	  or	  presumed	  to	  have	  occurred	  within	  the	  prior	  7	  days.	  UrNGAL	  =	  urine	  neutrophil	  gelatinase-­‐associated	  lipocalin.	  *	  Time	  to	  AKI	  by	  UrNGAL	  was	   analyzed	   in	   patients	   that	   fulfilled	   KDIGO	   and	   UrNGAL	   criteria	   for	   AKI	   (true	  positives).	  	  Figure	  2.1a	  shows	  mean	  SCr	  and	  UrNGAL	  data	  over	  time	  for	  the	  entire	  group	  of	   24	   patients,	   stratified	   by	   the	   presence	   or	   absence	   of	   AKI	   according	   to	  KDIGObin.	  Mean	  SCr	  among	  groups	  were	  similar	  at	  days	  0,	  1	  and	  3;	  at	  day	  2	  and	   from	  day	   4	   until	   day	   14,	   SCr	   levels	  were	   significantly	   higher	   in	   the	  AKI	  group	   (p	   ≤	   0.04	   for	   days	   2	   and	   8;	   p	   ≤	   0.01	   for	   all	   other	   time-­‐points).	   The	  highest	  SCr	  value	  of	  our	  dataset	  was	  2.2	  mg/dl,	  reached	  on	  day	  9	  in	  a	  patient	  receiving	  deoxycholate	  AmB.	  	  Figure	  2.1b	  shows	  mean	  SCr	  and	  Ur	  NGAL	  data	  over	   time	   for	   the	   entire	   group	   of	   24	   patients,	   stratified	   by	   the	   type	   of	   AmB	  preparation.	   Mean	   SCr	   levels	   were	   significantly	   higher	   in	   the	   deoxycholate	  than	   in	   the	   liposomal	  group	  on	  days	  4,	  10,	  11	  and	  12	  (p	  values	  =	  0.02,	  0.01,	  0.03,	  and	  0.01,	  respectively).	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a)	  Stratified	  by	  AKI	  according	  to	  KDIGO	  
	  b)	  Stratified	  by	  type	  of	  AmB	  preparation	  
	  
Figure	  2.1.	  Mean	  SCr	  and	  UrNGAL	  values	  during	  two	  weeks	  of	  treatment	  
with	   intravenous	   AmB.	   Legend:	   SCr	   =	   serum	   creatinine;	   Ur	   NGAL	   =	   urine	  neutrophil	   gelatinase-­‐associated	   lipocalin;	   AKI	   =	   acute	   kidney	   injury;	   AmB	   =	  amphotericin	   B;	   Deoxy	   =	   deoxycholate;	   Lipo	   =	   liposomal;	   KDIGO	   =	   kidney	   diseases	  improving	  global	  outcomes	  criterion	  that	  requires	  an	  increase	  in	  SCr	  by	  ≥	  0.3	  mg/dl	  within	   48	   hours;	   or	   an	   increase	   in	   SCr	   to	   ≥	   1.5	   times	   baseline,	   which	   is	   known	   or	  presumed	   to	   have	   occurred	  within	   the	   prior	   7	   days.	   Symbols	   (squares	   and	   circles)	  represent	  the	  mean	  and	  bars	  the	  standard	  error	  of	  the	  mean.	  SCr	  values	  (black)	  are	  plotted	  on	   the	  primary	  y	  axis	   	   (left)	   and	  Ur	  NGAL	   (gray)	  values	  on	   the	   secondary	  y	  axis	   (right).	   a)	   The	   AKI	   group	   is	   represented	   by	   squares	   and	   the	   no	   AKI	   group	   by	  circles.	  	  b)	  The	  Lipo	  group	  is	  represented	  by	  squares	  and	  the	  Deoxy	  group	  by	  circles.	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UrNGAL	  data	  	  	  Two-­‐hundred	   and	   fifty-­‐six	   UrNGAL	  measurements	   were	   performed	   over	   14	  days	  in	  24	  patients.	  We	  analyzed	  UrNGAL	  data	  in	  ng/ml	  and	  also	  normalized	  by	  urine	  creatinine	  excretion	  (μg/g	  urine	  creatinine)	  or	  by	  baseline	  values	  (%	  change	  from	  baseline).	  There	  was	  a	  strong	  correlation	  between	  UrNGAL	  in	  ng/ml	  and	  μg/g	  creatinine	  at	  all	  time	  points	  (Spearman's	  rho	  >	  0.80	  for	  days	  0,	  2,	  9	  and	  13;	  Spearman's	  rho	  >	  0.90	   for	   all	   other	   time	  points),	  with	   consistently	   higher	   levels	   in	   μg/g	  than	   in	   ng/ml	   (mean	   2.9x	   higher,	   range	   1.6x	   to	   5.1x	   on	   days	   9	   and	   11,	  respectively).	   However,	   standardized	   dispersion	   (SD/mean)	  was	   also	   higher	  at	   all	   time	   points	   for	   UrNGAL	   in	   μg/g	   creatinine	   versus	   ng/ml	   (mean	   1.4x	  higher,	  range	  1.1x	  to	  1.7x	  on	  days	  5	  and	  4,	  respectively).	  Since	  the	  diagnostic	  performance	  of	  UrNGAL	  was	  not	  improved	  by	  normalizing	  by	  urine	  creatinine,	  we	  chose	  to	  report	  the	  results	  in	  ng/ml.	  	  The	  correlation	  between	  UrNGAL	  in	  ng/ml	  and	  %	  increase	  over	  baseline	  was	  weaker	  (Spearman's	  rho	  coefficients	  ranging	  from	  0.27	  to	  0.60,	  at	  days	  5	  and	  3,	  respectively).	  Therefore,	  some	  analyses	  are	  also	  reported	  as	  %	  change	  from	  baseline.	  	  Mean	  UrNGAL	   levels	   (ng/ml)	  were	  not	   significantly	  different	   at	   any	  point	   in	  time	  when	  stratified	  by	  the	  presence	  or	  absence	  of	  AKI	  by	  KDIGObin	  criterion	  (Figure	   2.1a)	   or	   by	   type	   of	   AmB	   preparation	   (Figure	   2.1b)	   (p>0.05	   for	   all	  comparisons	   using	   non-­‐parametric	   tests).	   The	   only	   comparison	   that	  approached	  statistical	   significance	  was	   that	  of	   log-­‐transformed	  UrNGAL	  data	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on	  day	  5	  across	  AKI	  groups,	  when	  using	  NT0.5	  criterion	  (-­‐0.12	  ±	  1.32	  versus	  -­‐1.43	  ±	  1.62	  log	  ng/ml;	  AKI	  versus	  No	  AKI	  groups;	  p	  =	  0.053).	  	  As	   shown	   in	   Figure	  2.2,	   peak	  UrNGAL	   levels	  were	  numerically	   higher	   in	   the	  AKI	   than	   in	   the	   no	   AKI	   group,	   but	   the	   differences	   in	   means	   were	   not	  statistically	  significant	  (6.70	  ±	  7.22	  versus	  2.90	  ±	  1.90	  ng/ml;	  p=0.33).	  When	  stratified	   by	   AKI	   status	   across	   AmB	   subgroups,	   the	   highest	   peak	   UrNGAL	  values	  were	  observed	  in	  AKI	  patients	  in	  the	  deoxycholate	  (7.76	  ±	  7.71	  ng/ml)	  and	  liposomal	  subgroups	  (5.18	  ±	  6.73	  ng/ml),	  followed	  by	  No	  AKI	  patients	  the	  deoxycholate	   (3.12	   ±	   2.40	   ng/ml)	   and	   liposomal	   subgroups	   (2.81	   ±	   1.92	  ng/ml)	  (p	  for	  trend	  across	  ordered	  groups	  0.15).	  	  
	  	  
Figure	   2.2.	   Peak	   UrNGAL	   levels	   stratified	   by	   AKI	   status	   according	   to	  
KDIGO.	   Legend:	   data	   presented	   as	   mean	   and	   standard	   error	   of	   the	   mean.	  UrNGAL	  =	  urine	  neutrophil	  gelatinase-­‐associated	  lipocalin;	  AKI	  =	  acute	  kidney	  injury;	   KDIGO	   =	   kidney	   diseases	   improving	   global	   outcomes	   criterion	   that	  requires	  an	  increase	  in	  SCr	  by	  ≥	  0.3	  mg/dl	  within	  48	  hours;	  or	  an	  increase	  in	  SCr	  to	  ≥	  1.5x	  baseline,	  which	  is	  known	  or	  presumed	  to	  have	  occurred	  within	  the	   prior	   7	   days.	   Number	   of	   cases	   per	   group:	   AKI	   =	   17;	   No	   AKI	   =	   7;	  Deoxycholate	  subgroup,	  AKI	  =	  10	  and	  No	  AKI	  =	  2;	  Liposomal	  subgroup,	  AKI	  =	  7	   and	   No	   AKI	   =	   5.	   P	   for	   trend	   =	   0.15	   (order	   of	   groups	   for	   trend	   test:	  Deoxycholate	  AKI	  -­‐>	  Liposomal	  AKI	  -­‐>	  Deoxycholate	  no	  AKI	  -­‐>	  Liposomal	  No	  AKI).	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The	  highest	  UrNGAL	  level	  in	  our	  dataset	  was	  21.88	  ng/ml,	  achieved	  on	  day	  3	  in	   a	   patient	  who	  developed	  AKI	  while	   using	  deoxycholate	  AmB.	  The	  highest	  increase	  over	  baseline	  UrNGAL	  in	  our	  dataset	  was	  9,150.00%,	  achieved	  on	  day	  8,	  also	  in	  a	  patient	  receiving	  deoxycholate	  AmB.	  	  	  
Time	  to	  peak	  UrNGAL	  versus	  time	  to	  peak	  SCr	  in	  AKI	  patients	  	  Figure	  2.3a	  shows	  the	  distribution	  of	  the	  variable	  time	  to	  peak	  UrNGAL	  minus	  
time	  to	  peak	  SCr	  in	  the	  AKI	  group.	  In	  9	  patients,	  UrNGAL	  peaked	  before	  SCr;	  in	  5	   patients,	   the	   peaks	   were	   simultaneous	   and	   in	   3	   patients,	   UrNGAL	   peak	  occurred	  after	  SCr.	  In	  average,	  UrNGAL	  peaked	  1.5	  days	  earlier	  than	  SCr	  (6.8	  ±	  3.3	  versus	  8.2	  ±	  3.4	  days;	  time	  to	  peak	  UrNGAL	  and	  SCr,	  respectively;	  p	  =	  0.035	  one	  sample,	  paired	  t	  test).	  Results	  were	  identical	  when	  looking	  at	  UrNGAL	  in	  %	  increase	  over	  baseline.	  	   a)	  Time	  to	  peak	  UrNGAL	  minus	  time	  to	  peak	  SCr	  in	  AKI	  patients	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b)	  Time	  to	  AKI	  by	  UrNGAL	  (≥	  3x	  baseline)	  minus	  time	  to	  AKI	  by	  SCr	  criteria	  	  
	  
Figure	  2.3.	  Comparison	  of	  UrNGAL	  and	  SCr	  in	  time	  to	  peak	  values	  and	  
time	  to	  AKI.	  Legend:	  UrNGAL	  =	  urine	  neutrophil	  gelatinase-­‐associated	  lipocalin;	  SCr	  =	  serum	  creatinine;	  AKI	  =	  acute	  kidney	  injury.	  AKI	  was	  defined	  by	  KDIGO	  criterion	  in	  all	  analyses.	  a)	  Number	  of	  patients	  =	  17.	  Analyses	  with	  time	  to	  peak	  UrNGAL	  as	  defined	  by	  absolute	  values	  (ng/ml)	  or	  %	  change	  from	  baseline	  yielded	  identical	  results.	  b)	  Number	  of	  patients	  =	  13	  (concordant	  AKI	  diagnosis	  by	  both	  criteria).	  	  	  	  
Diagnosis	  of	  AKI	  by	  UrNGAL	  levels	  at	  a	  specific	  time-­‐point:	  ROC	  curves	  	  To	   test	   the	   diagnostic	   performance	   of	   UrNGAL	   in	   detecting	   AKI	   using	  KDIGObin	  SCr	   criteria	   as	   the	  gold	   standard,	  we	  performed	  ROC	  curves	  at	   all	  time	   points.	   UrNGAL	   levels	   on	   day	   5	  were	   associated	  with	   the	   highest	   AUC	  (0.68;	  95%	  CI	  0.41	  to	  0.95).	  As	  shown	  in	  Figure	  2.4,	  UrNGAL	  levels	  on	  day	  5	  were	  better	  predictors	  of	  AKI	  when	  analyzed	  in	  absolute	  (ng/ml)	  rather	  than	  relative	   values	   (%	   change	   from	   baseline).	   However,	   this	   performance	   of	  UrNGAL	  on	  day	  5	  was	  more	   likely	  due	   to	  consistently	   low	  UrNGAL	  values	   in	  the	  No	  AKI	  group	  instead	  of	  very	  elevated	  levels	  in	  the	  AKI	  group	  (0.50	  ±	  0.49	  versus	  2.32	  ±	  5.01	  ng/ml;	  No	  AKI	  versus	  AKI	  groups,	  respectively;	  p	  =	  0.21).	  A	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level	   of	  UrNGAL	  ≥	   0.37	   ng/ml	   on	   day	   5	  was	   associated	  with	   a	   sensitivity	   of	  81%,	  specificity	  of	  50%	  and	  accuracy	  of	  73%	  in	  detecting	  AKI.	  	  
	  
Figure	  2.4.	  Receiver	  operating	  characteristics	  (ROC)	  curves	  analyzing	  the	  
performance	  UrNGAL	  on	  day	  5	  in	  detecting	  AKI	  using	  KDIGO	  SCr	  criteria	  
as	   the	   gold	   standard.	   Legend:	   UrNGAL	   =	   urine	   neutrophil	   gelatinase-­‐associated	  lipocalin;	  SCr	  =	  serum	  creatinine;	  AKI	  =	  acute	  kidney	  injury;	  KDIGO	  =	   kidney	   diseases	   improving	   global	   outcomes	   criterion	   that	   requires	   an	  increase	  in	  SCr	  by	  ≥	  0.3	  mg/dl	  within	  48	  hours;	  or	  an	  increase	  in	  SCr	  to	  ≥	  1.5	  times	  baseline,	  which	  is	  known	  or	  presumed	  to	  have	  occurred	  within	  the	  prior	  7	   days.	   UrNGAL	   on	   day	   5	   was	   a	   better	   predictor	   of	   AKI	   when	   reported	   as	  ng/ml	   (compared	   to	   %	   change	   over	   baseline).	   	   All	   24	   patients	   (12	  deoxycholate	  and	  12	  liposomal)	  are	  included	  in	  this	  analysis.	  	  We	  tested	  whether	  changing	  the	  gold	  standard	  used	  to	  define	  AKI	  cases	  from	  KDIGObin	   to	   NT0.5	   or	   NT2x	   would	   change	   the	   diagnostic	   performance	   of	  UrNGAL.	   For	   both	   SCr	   criteria,	   UrNGAL	   levels	   on	   day	   5	   remained	   the	   best	  time-­‐point.	  However,	  whereas	  the	  use	  of	  NT0.5	  criterion	  yielded	  very	  similar	  findings	  (AUC	  on	  day	  5	  of	  0.69;	  95%	  CI	  0.42	  to	  0.95),	  using	  NT2x	  resulted	  in	  a	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worse	  diagnostic	  performance	  of	  UrNGAL	  (AUC	  on	  day	  5	  of	  0.46;	  95%	  CI	  0.09	  to	  0.83).	  All	   analyses	   were	   repeated	   using	   log-­‐transformed	   UrNGAL	   data	   as	   well	   as	  UrNGAL	   expressed	   in	   μg/g	   of	   urine	   creatinine	   or	   percent	   increase	   over	  baseline;	  all	  of	   these	  alternative	  ways	  of	  expressing	  UrNGAL	  data	  resulted	   in	  inferior	  diagnostic	  performance	  (data	  not	  shown).	  	  
Diagnosis	   of	   AKI	   by	   UrNGAL	   levels	   at	   a	   specific	   time-­‐point:	   subgroup	  
analyses	  (deoxycholate	  versus	  liposomal)	  	  Lastly,	   we	   repeated	   ROC	   analyses	   to	   test	   the	   diagnostic	   performance	   of	  UrNGAL	  (expressed	  in	  ng/ml)	  in	  the	  deoxycholate	  and	  liposomal	  subgroups.	  	  In	  the	  deoxycholate	  subgroup,	  the	  diagnostic	  performance	  of	  UrNGAL	  on	  day	  5	  was	  better	  than	  when	  considering	  the	  entire	  group.	  Using	  KDIGObin	  definition	  as	   gold	   standard,	   the	   AUC	   for	   UrNGAL	   on	   day	   5	   was	   0.89	   (95%	   CI	   0.67	   to	  1.00);	   an	   UrNGAL	   level	   ≥	   0.23	   ng/ml	   was	   associated	   with	   a	   sensitivity	   of	  88.9%,	  sensitivity	  of	  100%	  and	  accuracy	  of	  90.9%.	  Using	  NT0.5	  criterion,	  an	  UrNGAL	   on	   day	   5	   ≥	   0.23	   ng/ml	   resulted	   in	   a	   perfect	   fit	   (AUC	   =	   1.00,	   100%	  sensitivity,	   specificity	   and	   accuracy).	   This	   perfect	   discriminative	   ability	   of	  UrNGAL	   on	   day	   5	   when	   using	   NT0.5	   as	   the	   gold	   standard	   was	   due	   to	  consistently	  low	  levels	  in	  the	  NoAKI	  group	  (UrNGAL	  0.07	  ±	  0.08	  versus	  3.14	  ±	  6.88	  ng/ml	  in	  the	  NoAKI	  and	  AKI	  groups,	  respectively;	  p	  =	  0.01).	  	  In	   the	   liposomal	   group,	   the	   diagnostic	   performance	   of	   UrNGAL	   was	   worse.	  Here,	   the	  day	  associated	  with	   the	  best	  AUC	  was	  day	  6.	  The	  AUC	   for	  UrNGAL	  levels	  on	  day	  6	  was	  0.60	  (95%	  CI	  0.21	  to	  0.99);	  results	  were	  the	  same	  when	  using	  KDIGObin	  or	  NT0.5	  as	  gold	  standard.	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Diagnosis	  of	  AKI	  by	  UrNGAL:	  patient-­‐level	  analyses	  	  The	  UrNGAL	  cutoffs	  on	  day	  5	  identified	  by	  ROC	  curves	  were	  very	  low;	  in	  fact,	  they	  were	  consistent	  with	  baseline	  values.	  Moreover,	  by	  day	  5,	  one	  quarter	  of	  the	   patients	   already	   had	   the	   diagnosis	   of	   AKI	   established	   by	   SCr	   KDIGO	  criteria	  (time	  to	  AKI	  by	  KDIGObin	  =	  7.2	  ±	  3.1	  days,	  median	  7	  days,	  IQR	  5	  to	  9	  days).	  In	  some	  patients,	  UrNGAL	  had	  already	  peaked	  and	  declined	  by	  day	  5;	  in	  others,	  UrNGAL	  levels	  had	  not	  yet	  risen	  by	  day	  5.	  Since	  we	  were	  interested	  in	  finding	   if	  UrNGAL	   could	  detect	  AKI	   earlier	   than	  SCr,	  we	   reviewed	   individual	  patient-­‐level	  data.	  For	  these	  analyses,	  after	  carefully	  observing	  UrNGAL	  data,	  we	  chose	  an	  UrNGAL	  cutoff	  of	  ≥	  2.54	  ng/ml	  as	  the	  criterion	  for	  AKI.	  	  As	   illustrated	   in	   Table	   2.4a,	   using	   this	   cutoff	   and	   SCr	   KDIGObin	   as	   the	   gold	  standard,	  we	  found	  11	  true	  positives,	  3	  false	  positives,	  6	  false	  negatives	  and	  4	  true	  negatives	  (sensitivity	  64.7%;	  specificity	  57.1%;	  positive	  predictive	  value	  78.6%;	  negative	  predictive	  value	  40.0%;	  accuracy	  62.5%).	  
Table	  2.4.	  Diagnostic	  performance	  of	  UrNGAL:	  patient-­‐level	  analysis	  
	  a)	  Absolute	  (ng/ml)	  UrNGAL	  values	  	   AKI	  by	  SCr	  (KDIGO	  criteria)	   Total	  Yes	   No	  AKI	  by	  UrNGAL	  (≥	  2.54	  ng/ml)	   Yes	   11	   3	   14	  No	   6	   4	   10	  	   Total	   17	   7	   24	  	   	   	   	   	  b)	  Relative	  (%	  change	  from	  baseline)	  UrNGAL	  values	  	   AKI	  by	  SCr	  (KDIGO	  criteria)	   Total	  Yes	   No	   	  AKI	  by	  UrNGAL	  (≥	  3x	  baseline)	   Yes	   13	   5	   18	  No	   4	   2	   6	  	   Total	   17	   7	   24	  Legend:	   AKI	   =	   acute	   kidney	   injury;	   UrNGAL	   =	   urine	   neutrophil	   gelatinase-­‐associated	   lipocalin;	   SCr	   =	   serum	   creatinine;	   KDIGO	   =	   kidney	   diseases	  improving	  global	  outcomes	  criterion	  that	  requires	  an	  increase	  in	  SCr	  by	  ≥	  0.3	  mg/dl	  within	  48	  hours;	  or	  an	  increase	  in	  SCr	  to	  ≥	  1.5	  times	  baseline,	  which	  is	  known	  or	  presumed	  to	  have	  occurred	  within	  the	  prior	  7	  days.	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Figure	  2.5	  displays	  two	  examples	  of	  true	  positive	  cases.	  	  a)	  AKI	  diagnosed	  1	  day	  earlier	  by	  UrNGAL	  criteria	  
	  b)	  AKI	  diagnosed	  1	  day	  later	  by	  UrNGAL	  criteria	  
	  
Figure	  2.5.	  Representative	  examples	  of	  true	  positive	  cases	  by	  UrNGAL	  (≥	  
2.54	   ng/ml)	   criteria,	   considering	   SCr	   (KDIGO)	   criteria	   as	   the	   gold	  
standard.	   Legend:	   AKI	   =	   acute	   kidney	   injury;	   UrNGAL	   =	   urine	   neutrophil	  gelatinase-­‐associated	   lipocalin;	   SCr	   =	   serum	   creatinine;	   KDIGO	   =	   kidney	  diseases	  improving	  global	  outcomes;	  Amb	  =	  amphotericin	  B.	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  a)	  True	  Negative	  
	  b)	  False	  Positive	  
	  c)	  False	  Negative	  
	  
Figure	  2.6.	  Representative	  examples	  of	   true	  negative,	   false	  positive	  and	  false	  negative	  
cases	  by	  UrNGAL	  (≥	  2.54	  ng/ml)	  criteria,	  with	  SCr	  (KDIGO)	  criteria	  as	  the	  gold	  standard.	  Legend:	   AKI	   =	   acute	   kidney	   injury;	   Ur	   NGAL	   =	   urine	   neutrophil	   gelatinase-­‐associated	   lipocalin;	   SCr	   =	  serum	  creatinine;	  KDIGO	  =	  kidney	  diseases	  improving	  global	  outcomes;	  Amb	  =	  amphotericin	  B.	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Figure	   2.6	   displays	   representative	   true	   negative,	   false	   positive	   and	   false	  negative	   cases.	   Changing	   the	   gold	   standard	   to	   NT0.5	   resulted	   in	   a	   worse	  diagnostic	  performance	  due	  to	  an	   increased	  frequency	  of	   false	  positive	  cases	  (from	  3	  to	  5).	  We	  had	  two	  cases	  in	  which	  baseline	  UrNGAL	  was	  ≥	  2.54	  ng/ml.	  In	  the	  first	  of	  these	  cases,	  baseline	  UrNGAL	  was	  4.20	  ng/ml,	  but	   levels	   from	  days	  1	   thru	  5	  were	  all	  <	  1.0	  ng/ml.	  On	  day	  6,	  UrNGAL	  increased	  to	  6.5	  ng/ml	  and	  peaked	  at	  21.3	  ng/ml	  on	  day	  7.	  This	  patient	  reached	  AKI	  by	  KDIGObin	  on	  day	  10	  and	  was	  thus	   considered	   a	   true	   positive.	   In	   the	   second	   case,	   baseline	   UrNGAL	   was	  13.90	  ng/ml.	  He	  reached	  AKI	  diagnosis	  by	  KDIGObin	  on	  day	  8.	  UrNGAL	  levels	  varied	  from	  16.58	  ng/ml	  on	  day	  1	  to	  3.58	  ng/ml	  on	  day	  8;	  peak	  UrNGAL	  level	  for	   this	   patient	  was	  19.63	  ng/ml	   on	  day	  13.	   Since	   this	  was	   only	  1.4x	  higher	  than	  the	  baseline	  value,	  we	  considered	  this	  a	  false	  negative	  case.	  	  	  We	   tested	   whether	   analyzing	   UrNGAL	   levels	   as	   a	   %	   change	   from	   baseline	  values	   would	   influence	   the	   diagnostic	   performance	   of	   this	   biomarker.	   For	  these	  analyses,	  we	  chose	  an	  UrNGAL	  cutoff	  of	  ≥	  3x	  higher	  than	  baseline	  as	  the	  criterion	   for	   AKI.	   As	   illustrated	   in	   Table	   2.4b,	   using	   this	   cutoff	   and	   SCr	  KDIGObin	  as	  the	  gold	  standard,	  we	  found	  13	  true	  positives,	  5	  false	  positives,	  4	  false	   negatives	   and	   2	   true	   negatives	   (sensitivity	   76.5%;	   specificity	   28.6%;	  positive	   predictive	   value	   72.2%;	   negative	   predictive	   value	   33.3%;	   accuracy	  62.5%).	  Changing	   the	  gold	   standard	   to	  NT0.5	   resulted	   in	   a	  worse	  diagnostic	  performance	  due	  to	  an	  increased	  frequency	  of	  false	  positive	  cases	  (from	  5	  to	  7).	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Time	  to	  AKI	  in	  by	  UrNGAL	  criteria	  	  	  Using	   a	   cutoff	   of	   UrNGAL	   ≥	   2.54	   ng/ml,	   14	   cases	   of	   AKI	  were	   detected	   at	   a	  mean	   of	   5.2	   ±	   4.1	   days.	   However,	   3	   of	   theses	   cases	   were	   considered	   false	  positive	   by	   KDIGObin	   criterion.	   In	   11	   cases,	   the	   diagnosis	   of	   AKI	   was	  concordant	   between	   UrNGAL	   and	   SCr	   (KDIGO	   bin)	   criteria.	   In	   these	   11	  concordant	  cases,	  AKI	  was	  detected,	  on	  average,	  1.7	  days	  earlier	  by	  UrNGAL	  when	  compared	  to	  SCr	  criteria	  (5.2	  ±	  3.8	  versus	  6.9	  ±	  3.5	  days,	  UrNGAL	  and	  SCr	   criteria,	   respectively;	   p	  =	  0.06).	  UrNGAL	  detected	  AKI	   earlier	   in	  5	   cases,	  whereas	  SCr	  prevailed	  in	  2	  cases;	  in	  the	  remaining	  4,	  the	  diagnosis	  of	  AKI	  was	  made	  on	  the	  same	  day	  by	  both	  methods.	  	  	  Similar	  analyses	  were	  performed	  using	  a	  cutoff	  of	  UrNGAL	  ≥	  3x	  baseline;	  18	  cases	  of	  AKI	  were	  detected	  at	  a	  mean	  of	  3.1	  ±	  2.4	  days.	  However,	  5	  of	   these	  cases	  were	   considered	   false	  positive	  by	  KDIGObin	   criterion.	   In	  13	   cases,	   the	  diagnosis	   was	   concordant	   between	   UrNGAL	   (≥	   3x	   baseline)	   and	   SCr	  (KDIGObin)	   criteria.	   In	   these	   13	   concordant	   cases,	   AKI	   was	   detected,	   on	  average,	  3.2	  days	  earlier	  by	  UrNGAL	  when	  compared	  to	  SCr	  criteria	  (3.7	  ±	  2.5	  versus	  6.9	  ±	  3.3	  days,	  UrNGAL	  and	  SCr	  criteria,	  respectively;	  p	  =	  0.001).	  	  Figure	  2.3b	  shows	  the	  distribution	  of	  the	  variable	  time	  to	  AKI	  by	  UrNGAL	  minus	  
time	  to	  AKI	  by	  SCr	  in	  the	  13	  concordant	  cases.	  UrNGAL	  detected	  AKI	  earlier	  in	  11	  cases,	  whereas	  SCr	  prevailed	  in	  1	  case;	  in	  the	  remaining	  1,	  the	  diagnosis	  of	  AKI	  was	  made	  on	  the	  same	  day	  by	  both	  methods.	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DISCUSSION	  	  We	   have	   prospectively	   measured	   daily	   SCr	   and	   UrNGAL	   in	   24	   non-­‐septic,	  hemodynamically	   stable	   patients,	   treated	  with	   AmB.	   Our	   data	   suggests	   that	  UrNGAL	   has	   the	   potential	   to	   detect	   AmB-­‐induced	   AKI	   earlier	   than	   the	  most	  sensitive	  SCr-­‐based	  criteria	  (KDIGO).	  	  To	  our	  knowledge,	  this	  is	  the	  first	  study	  to	  evaluate	  the	  role	  of	  UrNGAL	  in	  the	  early	  diagnosis	  of	  AmB-­‐induced	  AKI.	  	  Since	   the	  development	  of	  RIFLE	  (8)	  and	  AKIN	  (9)	  criteria	  and	  publication	  of	  the	   recent	   KDIGO	   guidelines	   (46),	   the	   SCr	   cutoffs	   to	   define	   AKI	   are	   well	  establised.	  On	  the	  other	  hand	  there	  is	  still	  no	  consensus	  on	  how	  UrNGAL	  levels	  should	   be	   reported	   or	   which	   cutoffs	   should	   be	   used	   to	   define	   AKI.	   Several	  authors	   report	   UrNGAL	   levels	   as	   absolute	   ng/ml	   while	   others	   normalize	  UrNGAL	   for	   urine	   creatinine	   excretion	   (μg/g	   urine	   creatinine);	   less	   often,	  UrNGAL	   levels	   have	   been	   reported	   as	  %	   change	   from	   baseline	   (42).	   In	   our	  analyses,	   normalization	   for	   urine	   creatinine	   increased	   mean	   values	   but	  worsened	   the	   diagnostic	   performance	   of	   UrNGAL	   due	   to	   increased	   data	  dispersion.	  On	  the	  other	  hand,	  normalization	  for	  baseline	   levels	  did	  offer	  the	  advantage	  of	  equalizing	  all	  baseline	  levels	  and	  facilitating	  the	  establishment	  of	  a	   cutoff	   value	   (such	   as	   3x	   increase	   over	   baseline).	   Nevertheless,	   since	   all	  subsequent	   values	   are	   dependent	   upon	   the	   baseline	   value,	   this	   approach	   is	  disadvantageous	  when	  the	  baseline	  value	  is	  a	  significant	  outlier.	  In	   studies	  of	  AKI	  post	   cardiac	   surgery,	  UrNGAL	   starts	   to	   rise	   as	   early	   as	  1-­‐2	  hours	   after	   cardiopulmonary	   bypass.	   In	   studies	   of	   contrast-­‐induced	  nephropathy,	   UrNGAL	   has	   been	   measured	   anywhere	   from	   2-­‐24	   hours	   after	  
66	  	  
contrast	   administration.	   The	   best	   timing	   of	   urine	   collection	   in	   studies	   of	  antimicrobial	   agents-­‐related	   nephrotoxicity	   is	   not	   known.	   Gaspari	   et	   al.	  measured	   UrNGAL	   at	   1	   and	   4	   h	   and	   1,	   2,	   3,	   7	   and	   15	   days	   after	   cisplatin	  administration	  and	  found	  that	  UrNGAL	  levels	  started	  to	  rise	  only	  after	  the	  first	  day	  (42).	  Considering	  their	  findings,	  we	  chose	  to	  measure	  UrNGAL	  at	  baseline	  and	  daily	  after	  initiation	  of	  AmB.	  	  	  When	   looking	  at	   the	  entire	  group,	  UrNGAL	  on	  day	  5	  was	  associated	  with	  an	  AUC	  of	  0.68	  (95%	  CI	  0.41	  to	  0.95)	   for	  the	  diagnosis	  of	  AKI	  (by	  KDIGObin).	  A	  level	   of	  UrNGAL	  ≥	   0.37	   ng/ml	   on	   day	   5	  was	   associated	  with	   a	   sensitivity	   of	  81%,	   specificity	  of	  50%	  and	  accuracy	  of	  73%	   in	  detecting	  AKI.	   In	   individual	  case	  analyses,	  we	  chose	  an	  UrNGAL	  cutoff	  of	  ≥	  2.54	  ng/ml	  as	   the	  criteria	   for	  AKI.	   In	   these	   analyses,	   UrNGAL	   was	   associated	   with	   a	   sensitivity	   64.7%;	  specificity	   57.1%;	  positive	  predictive	   value	  78.6%;	  negative	  predictive	   value	  40.0%;	  and	  accuracy	  62.5%.	  This	  diagnostic	  performance	  is	  somewhat	  inferior	  to	   that	   of	   studies	   of	   UrNGAL	   in	   other	   settings.	   In	   2008,	   Coca	   et	   al.	   (47)	  systematically	   reviewed	   the	   literature	   and	   encountered	   four	   studies	   of	   good	  quality	  that	  investigated	  the	  role	  of	  UrNGAL	  as	  an	  early	  biomarker	  of	  AKI.	  Two	  of	  these	  studies	  were	  in	  the	  setting	  of	  cardiac	  surgery	  (16,	  19),	  one	  in	  critically	  ill	  children	  (48)	  and	  one	  post-­‐renal	  transplant	  (49).	  The	  sensitivity	  of	  UrNGAL	  for	  early	  detection	  of	  AKI	  varied	  from	  73%	  (19)	  to	  100%	  (16),	  specificity	  from	  72%	   (48)	   to	  98%	   (16),	   and	  AUC	   from	  78%	   (19)	   to	  99.8%	   (16).	  Only	  one	  of	  these	  studies	   looked	  at	  the	  ability	  of	  UrNGAL	  to	  predict	  AKI	  severity	  and	  did	  not	   find	   a	   strong	   association	   (48).	   Similarly,	   we	   did	   not	   find	   an	   association	  between	  AKI	  severity	  and	  UrNGAL	  levels	  in	  the	  present	  study.	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UrNGAL	   levels	   tended	   to	  be	  higher	   in	  users	  of	  deoxycholate	   than	   in	  users	  of	  liposomal	   AmB,	   even	   when	   controlling	   for	   AKI	   status.	   When	   we	   analyzed	  subgroups	  of	  AmB	  preparation,	  we	  found	  a	  better	  diagnostic	  performance	  of	  UrNGAL	   for	   the	   detection	   of	   AKI	   in	   patients	   receiving	   deoxycholate	   than	  liposomal	   AmB.	   Using	   KDIGObin	   definition	   as	   gold	   standard,	   the	   AUC	   for	  UrNGAL	   on	   day	   5	  was	   0.89	   (95%	   CI	   0.67	   to	   1.00);	   an	   UrNGAL	   level	   ≥	   0.23	  ng/ml	   was	   associated	   with	   a	   sensitivity	   of	   88.9%,	   sensitivity	   of	   100%	   and	  accuracy	  of	  90.9%.	  Using	  NT0.5	  criterion,	  an	  UrNGAL	  on	  day	  5	  ≥	  0.23	  ng/ml	  resulted	  in	  a	  perfect	  fit	  (AUC	  1.0).	  	  In	   2009,	   Haase	   and	   coworkers	   also	   conducted	   a	   systematic	   review	   and	  metanalysis	  of	  NGAL	  for	  the	  diagnosis	  of	  AKI	  (14).	  When	  looking	  at	  individual	  studies,	   the	   authors	   found	   that	   UrNGAL	   cutoffs	   used	   for	   prediction	   of	   AKI	  varied	   widely,	   differing	   more	   than	   50	   times	   from	   the	   lowest	   (48)	   to	   the	  highest	   (50)	   reported	   values.	   In	   analyses	   of	   the	   pooled	   diagnostic	   and	  prognostic	  accuracy	  of	  NGAL,	  these	  authors	  found	  cutoffs	  that	  were	  almost	  3	  times	  higher	  in	  studies	  of	  cardiac	  surgery	  than	  in	  studies	  of	  contrast-­‐induced	  nephropathy.	  This	  suggests	   that	   the	  context	   in	  which	   the	  renal	   injury	  occurs	  might	  have	  an	  impact	  on	  UrNGAL	  levels.	  The	  UrNGAL	  levels	  that	  we	  found	  in	  our	  study	  are	  similar	  to	  those	  reported	  Gaspari	  in	  recipients	  of	  cisplatin	  (42)	  and	  by	  Zappitelli	  et	  al.	  in	  critically	  ill	  children	  (48)	  but	  much	  lower	  than	  those	  encountered	  in	  all	  studies	  of	  cardiac	  surgery.	  There	  are	  no	  similar	  studies	  with	  AmB	   for	   comparison.	   Perhaps	   the	   less	   intense	   renal	   injury	   caused	   by	   drug	  nephrotoxicity	   was	   responsible	   for	   the	   overall	   low	   levels	   of	   UrNGAL.	   The	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lower	  UrNGAL	  levels	  found	  in	  recipients	  of	  liposomal	  than	  deoxycholate	  AmB	  likely	  reflects	  the	  better	  safety	  profile	  of	  the	  liposomal	  preparation.	  	  Our	  study	  has	  certain	  limitations.	  Since	  we	  measured	  UrNGAL	  approximately	  24	  hours	  after	  each	  dose	  of	  AmB,	  we	  cannot	  rule	  out	  an	  early	  UrNGAL	  peak.	  Although	  we	  were	  able	  to	  detect	  a	  significant	  difference	  in	  mean	  time	  to	  AKI	  by	  UrNGAL	  versus	  SCr	  criteria,	  we	  might	  have	  been	  underpowered	  for	  other	  comparisons,	   especially	   when	   looking	   at	   subgroups	   of	   AmB	   preparation.	  Moreover,	   our	   time	   to	   AKI	   analyses	   considered	   only	   paired	   matches	   of	  concordant	  cases	  (true	  positives),	  which	   is	  not	  a	  real	  world	  scenario.	  Similar	  to	  any	  study	  of	  urine	  biomarkers,	  the	  use	  of	  SCr	  as	  gold	  standard	  is	  in	  itself	  a	  limitation.	   Could	   UrNGAL	   elevation	   in	   patients	   without	   AKI	   by	   SCr	   criteria	  (false	   positive)	   represent	   “subclinical	   AKI”?	   Some	   experts	   currently	  recommend	  that,	   in	  the	  right	  clinical	  setting,	  renal	  tubular	   injury	  biomarkers	  may	   be	   used	   to	   diagnose	   AKI	   even	   in	   the	   absence	   of	   elevations	   in	   SCr	   or	  reductions	  in	  urine	  output	  as	  required	  by	  RIFLE	  and	  AKIN	  criteria	  (51).	  On	  the	  other	  hand,	   SCr	  elevations	  with	   low	  UrNGAL	   levels	   (false	  negative)	   could	  be	  due	   to	   a	   pre-­‐renal	   state	   without	   overt	   tubular	   injury.	   Indeed,	   a	   significant	  component	  of	  AmB	  nephrotoxicity	  is	  due	  to	  direct	  renal	  vasoconstriction	  (52–54).	   Finally,	   recent	   data	   suggests	   that	   pyuria	   is	   an	   important	   potential	  confounder	  when	  measuring	  UrNGAL	   (55).	  We	  did	  not	  have	  urinalysis	   in	   all	  patients,	   but	   our	   sample	   was	   comprised	   mostly	   of	   young	   men,	   in	   whom	  urinary	   tract	   infections	   would	   be	   uncommon.	   Additionally,	   no	   patients	  complained	  of	  urinary	  symptoms	  or	  had	  fever	  or	  leucocytosis.	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In	  summary,	  we	  found	  that	  UrNGAL	  was	  able	  to	  significantly	  shorten	  the	  time	  to	  detection	  of	  AmB-­‐induced	  AKI,	  even	  when	  compared	  to	  the	  most	  sensitive	  SCr-­‐based	  criteria.	  The	  diagnostic	  performance	  of	  UrNGAL	  against	  SCr-­‐based	  criteria	  was	  moderate	  when	   looking	   at	   the	   entire	   group	  but	   excellent	   in	   the	  deoxycholate	   subgroup.	   Finally,	   UrNGAL	   levels	   were	   higher	   in	   recipients	   of	  deoxycholate	  than	  liposomal	  AmB.	  	  Future	   studies	   should	   be	   conducted	   to	   evaluate	   if	   a	   UrNGAL-­‐oriented	  treatment	  strategy	  will	  result	  in	  a	  reduction	  in	  the	  incidence	  of	  AmB-­‐induced	  AKI	   (as	   defined	   by	   SCr-­‐based	   criteria),	   as	  well	   as	   in	   hospital	   stay	   and	   costs.	  When	  facing	  a	  significant	  elevation	  in	  UrNGAL	  prior	  to	  an	  elevation	  in	  SCr,	  the	  physician	  could	  institute	  one	  (or	  a	  combination)	  of	  several	  measures,	  such	  as	  switch	  from	  a	  deoxycholate	  to	  a	  liposomal	  preparation,	  change	  the	  treatment	  regimen	  (reduce	  the	  dose,	  switch	  to	  alternate	  days	  or	  temporarily	  discontinue	  AmB),	   or	   try	   volume	  expansion	  with	   intravenous	  0.9%	   sodium	  chloride.	  We	  believe	   that	  our	   findings	  with	  UrNGAL	   in	  AmB-­‐induced	  AKI	   in	   leishmaniasis	  patients	   could	   serve	   as	   a	   basis	   for	   the	   investigation	   of	   this	   and	   other	   urine	  biomarkers	   in	   the	   early	   detection	   of	   drug	   nephrotoxicity	   in	   various	   clinical	  settings.	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